{ "instance": { "vir-20211231.htm": { "axisCustom": 0, "axisStandard": 30, "contextCount": 318, "dts": { "calculationLink": { "local": [ "vir-20211231_cal.xml" ] }, "definitionLink": { "local": [ "vir-20211231_def.xml" ] }, "inline": { "local": [ "vir-20211231.htm" ] }, "labelLink": { "local": [ "vir-20211231_lab.xml" ] }, "presentationLink": { "local": [ "vir-20211231_pre.xml" ] }, "schema": { "local": [ "vir-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 898, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 31, "http://www.vir.bio/20211231": 27, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 62 }, "keyCustom": 179, "keyStandard": 462, "memberCustom": 81, "memberStandard": 40, "nsprefix": "vir", "nsuri": "http://www.vir.bio/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Fair Value Measurements", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Acquisitions", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:GrantAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Grant Agreements", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreements", "shortName": "Grant Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:GrantAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Collaboration and License Agreements", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements", "shortName": "Collaboration and License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Balance Sheet Components", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Commitments and Contingencies", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Related Party Transactions", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:TemporaryEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Convertible Preferred Stock", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock", "shortName": "Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:TemporaryEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:ConvertiblePreferredStockWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Convertible Preferred Stock Warrant Liability", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability", "shortName": "Convertible Preferred Stock Warrant Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:ConvertiblePreferredStockWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Stock-Based Awards", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwards", "shortName": "Stock-Based Awards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Net Income (Loss) Per Share", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShare1", "shortName": "Net Income (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Defined Contribution Plan", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlan", "shortName": "Defined Contribution Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Income Taxes", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Subsequent Event", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEvent1", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_USDollarShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_USDollarShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Stock-Based Awards (Tables)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables", "shortName": "Stock-Based Awards (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Net Income (Loss) Per Share (Tables)", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables", "shortName": "Net Income (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Income Taxes (Tables)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_e52b7462-3e95-4a90-a2ac-eeb96cc91696", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Organization - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "shortName": "Organization - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_e52b7462-3e95-4a90-a2ac-eeb96cc91696", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "vir:FinancialAssetsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails", "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "vir:FinancialAssetsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_c65e2fa1-651b-49f1-8130-e10a86ed4b23", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails", "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_c65e2fa1-651b-49f1-8130-e10a86ed4b23", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_f999fb4c-9967-4386-a71c-e0a64a7891bc", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "shortName": "Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_f999fb4c-9967-4386-a71c-e0a64a7891bc", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Operations", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_7a978f36-d4af-4db5-8584-15add2567749", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails", "shortName": "Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_7a978f36-d4af-4db5-8584-15add2567749", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Acquisitions - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "shortName": "Acquisitions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0bfd36b8-2f16-49a7-94eb-eb8361039f4e", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_4d962b66-b38e-4b66-95b7-9a327531b9c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "shortName": "Goodwill and Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "INF", "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails", "shortName": "Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_f506a175-6fde-4e73-bbbc-20e846b33555", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueNotFromContractWithCustomer", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Grant Agreements - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "shortName": "Grant Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "vir:GrantAgreementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_064e544a-5338-44a5-8d21-57da4323d0ff", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueNotFromContractWithCustomer", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Collaboration and License Agreements - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "shortName": "Collaboration and License Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_4535e3d1-cadf-43e9-a70d-52008cd60dfc", "decimals": "-2", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Balance Sheet Components - Schedule of Property and Equipment Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Balance Sheet Components - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "shortName": "Balance Sheet Components - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "vir:MilestonePayable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails", "shortName": "Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "vir:MilestonePayable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "role": "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:LeaseArrangementContractualExpirationBeginningYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "vir:LeaseArrangementContractualExpirationBeginningYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails", "shortName": "Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "vir:OperatingLeaseIncentiveOverLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails", "shortName": "Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "vir:OperatingLeaseIncentiveOverLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_931f9106-3768-4f05-bd7b-0855dd2f9745", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_1c598293-0936-4d1f-99f5-0722e4f7437e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Convertible Preferred Stock - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "shortName": "Convertible Preferred Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "vir:TemporaryEquityTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "0", "lang": null, "name": "vir:NumberOfClassOfStock", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0c0012f8-5960-4879-bdde-f46b368e2ae9", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Convertible Preferred Stock Warrant Liability - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails", "shortName": "Convertible Preferred Stock Warrant Liability - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0c0012f8-5960-4879-bdde-f46b368e2ae9", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_7d78f477-8e15-46ec-9ae7-c436d7a5b269", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Stock-Based Awards - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "shortName": "Stock-Based Awards - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_7d78f477-8e15-46ec-9ae7-c436d7a5b269", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_bb04a465-c3d8-4109-889c-c33e0ccca055", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails", "shortName": "Stock-Based Awards - Summary of Stock Option Plans Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_7ea779b6-e470-44f4-8cd2-792b82ad5755", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails", "shortName": "Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_e5046b1c-890a-4d88-9c47-8d81f489b3cf", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_c8189099-45c1-41f2-b6ca-954b37c65618", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_6a0b0601-deb2-4157-ba2f-7613b7f73ba3", "decimals": "-3", "lang": null, "name": "us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "shortName": "Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_1fafc9fa-e7af-46b8-b3e5-ea3f4a5ecd6e", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_c2a50417-42a1-40be-8caf-f0cebc94ffff", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails", "shortName": "Stock-Based Awards - Summary of Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_c2a50417-42a1-40be-8caf-f0cebc94ffff", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails", "shortName": "Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "0", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "shortName": "Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "0", "first": true, "lang": null, "name": "vir:EstimatedSharesEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Net Income (Loss) Per Share (Additional Information) (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails", "shortName": "Net Income (Loss) Per Share (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "0", "first": true, "lang": null, "name": "vir:EstimatedSharesEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Defined Contribution Plan - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails", "shortName": "Defined Contribution Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Income Taxes - Schedule of Loss Before Provision for (Benefit from) Income Taxes (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails", "shortName": "Income Taxes - Schedule of Loss Before Provision for (Benefit from) Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails", "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails", "shortName": "Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_1c598293-0936-4d1f-99f5-0722e4f7437e", "decimals": "-3", "first": true, "lang": null, "name": "vir:InitialPublicOfferingCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_1c598293-0936-4d1f-99f5-0722e4f7437e", "decimals": "-3", "first": true, "lang": null, "name": "vir:InitialPublicOfferingCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_68d98f4f-0d83-475e-8b52-0b892db80670", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_69329fa9-5ba5-4337-a561-386bfedc0568", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_69329fa9-5ba5-4337-a561-386bfedc0568", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_4d962b66-b38e-4b66-95b7-9a327531b9c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails", "shortName": "Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_1ad51e18-a052-4618-9f7f-dd217928f54d", "decimals": "-5", "first": true, "lang": null, "name": "vir:CashGrantAwarded", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Subsequent Event - Additional Information (Details)", "role": "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "shortName": "Subsequent Event - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_1ad51e18-a052-4618-9f7f-dd217928f54d", "decimals": "-5", "first": true, "lang": null, "name": "vir:CashGrantAwarded", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100090 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Organization", "role": "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vir-20211231.htm", "contextRef": "C_0125c984-0483-44b4-9fe9-ea8280d5aef7", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 126, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China Territory" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r750", "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r750", "r751", "r752" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r750", "r751", "r752" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r750", "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r753" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r748" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "verboseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r756" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "verboseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r750", "r751", "r752" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r746" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r749" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r56", "r58", "r121", "r122", "r283", "r293" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r282", "r292", "r399", "r409", "r640", "r641", "r642", "r643", "r644", "r645", "r647", "r706", "r709", "r743", "r744" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r282", "r292", "r399", "r409", "r640", "r641", "r642", "r643", "r644", "r645", "r647", "r706", "r709", "r743", "r744" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r200", "r305", "r307", "r649", "r705", "r707" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r200", "r305", "r307", "r649", "r705", "r707" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r282", "r292", "r334", "r399", "r409", "r640", "r641", "r642", "r643", "r644", "r645", "r647", "r706", "r709", "r743", "r744" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r282", "r292", "r334", "r399", "r409", "r640", "r641", "r642", "r643", "r644", "r645", "r647", "r706", "r709", "r743", "r744" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r57", "r58", "r121", "r122", "r283", "r293" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r201", "r202", "r305", "r308", "r708", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r201", "r202", "r305", "r308", "r708", "r727", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r204", "r627" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r640", "r642", "r645", "r743", "r744" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "stpr_OR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OREGON", "terseLabel": "Oregon" } } }, "localname": "OR", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "ASC 606" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASU 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201704Member": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2017-04 Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.", "label": "Accounting Standards Update 2017-04 [Member]", "terseLabel": "ASU 2017-04" } } }, "localname": "AccountingStandardsUpdate201704Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201813Member": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.", "label": "Accounting Standards Update 2018-13 [Member]", "terseLabel": "ASU 2018-13" } } }, "localname": "AccountingStandardsUpdate201813Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201814Member": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-14 Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans.", "label": "Accounting Standards Update 2018-14 [Member]", "terseLabel": "ASU 2018-14" } } }, "localname": "AccountingStandardsUpdate201814Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201818Member": { "auth_ref": [ "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.", "label": "Accounting Standards Update 2018-18 [Member]", "terseLabel": "ASU 2018-18" } } }, "localname": "AccountingStandardsUpdate201818Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44", "r633" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r8", "r29", "r205", "r206" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Receivable from collaboration", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r104" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "(Accretion of discounts) amortization of premiums on investments, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r22", "r672", "r688" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Accrued income taxes" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued and other liabilities", "totalLabel": "Total accrued and other liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r13", "r15", "r47" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Other professional and consulting expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r13", "r15", "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r43", "r250" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r32", "r63", "r64", "r65", "r691", "r717", "r721" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r62", "r65", "r75", "r76", "r77", "r124", "r125", "r126", "r546", "r712", "r713", "r761" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Estimated remaining useful lives" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r30", "r454", "r633" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r124", "r125", "r126", "r451", "r452", "r453", "r570" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r127", "r128", "r129", "r130", "r139", "r208", "r209", "r216", "r217", "r218", "r219", "r220", "r221", "r268", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r492", "r493", "r494", "r495", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r621", "r651", "r652", "r653", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r411", "r413", "r457", "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "auth_ref": [ "r296", "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.", "label": "Adjustments to Additional Paid in Capital, Stock Split", "negatedLabel": "Settlement of fractional shares from reverse stock split" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r413", "r443", "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r103", "r235", "r243" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "totalLabel": "Amortization of Intangible Assets, Total", "verboseLabel": "Amortization expense of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive shares excluded from calculation of diluted net loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r527", "r528", "r529", "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Asset acquisition purchase price", "totalLabel": "Asset Acquisition, Consideration Transferred, Total" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "auth_ref": [ "r527", "r528", "r529" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable", "terseLabel": "Value of common stock shares Issued for milestone payment" } } }, "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [ "r527", "r528", "r529", "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Asset acquisition, transaction costs" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiability": { "auth_ref": [ "r526" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.", "label": "Asset Acquisition, Contingent Consideration, Liability", "terseLabel": "Estimated fair value of contingent consideration", "totalLabel": "Asset Acquisition, Contingent Consideration, Liability, Total" } } }, "localname": "AssetAcquisitionContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r526" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current.", "label": "Asset Acquisition, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration recognized" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r115", "r183", "r192", "r198", "r214", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r541", "r547", "r582", "r631", "r633", "r671", "r687" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r54", "r115", "r214", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r541", "r547", "r582", "r631", "r633" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueAdjustment": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.", "label": "Assets, Fair Value Adjustment", "terseLabel": "Change in fair value of equity investments" } } }, "localname": "AssetsFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AustralianTaxationOfficeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Australia.", "label": "Australian Taxation Office [Member]", "terseLabel": "Australian Taxation Office" } } }, "localname": "AustralianTaxationOfficeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r414", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r554", "r558" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r681" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Bank Time Deposits" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r391", "r405" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r391", "r405", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Business acquisition, transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Business acquisition, shares issued" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r524" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill expected to be deductible for income tax purposes" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r515", "r516", "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business acquisition purchase price", "totalLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r515", "r516" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Business acquisition, shares issued value" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r102", "r525" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in estimated fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r523" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Milestone payments aggregate amount payable, maximum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r514", "r517", "r522" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration recognized", "totalLabel": "Business Combination, Contingent Consideration, Liability, Total", "verboseLabel": "Estimated fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r514", "r518" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration, current portion" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Fair value contingent consideration measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r514", "r518" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration, noncurrent" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r107", "r108", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment purchases included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r39", "r105" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r18", "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r18", "r106", "r668" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents and investments", "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r100", "r105", "r110" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash and cash equivalents at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash and cash equivalents at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r100", "r593" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r114", "r115", "r142", "r147", "r155", "r157", "r159", "r168", "r169", "r170", "r214", "r269", "r274", "r275", "r276", "r280", "r281", "r290", "r291", "r294", "r295", "r582", "r754" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.", "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable", "verboseLabel": "Warrant, expiration date" } } }, "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants issued, exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class Of Warrant Or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrant to purchase of convertible preferred stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r301", "r412" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class Of Warrant Or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r532", "r533", "r537" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration and License Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r50", "r257", "r676", "r695" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r254", "r255", "r256", "r264", "r731" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r124", "r125", "r570" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "verboseLabel": "Common stock price per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r28", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r28", "r633" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2021 and 2020, respectively; 127,416,740 and 107,648,925 shares issued and outstanding as of December 31, 2021 and 2020, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r70", "r72", "r73", "r81", "r679", "r699" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ContractBasedIntangibleAssetsMember": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.", "label": "Contract-Based Intangible Assets [Member]", "terseLabel": "Contract-Based Intangible Asset" } } }, "localname": "ContractBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r302", "r303", "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue", "totalLabel": "Contract with Customer, Liability, Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r302", "r303", "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Contract liability" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r290", "r291", "r294" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r86", "r115", "r214", "r269", "r270", "r271", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r582" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenue", "totalLabel": "Cost of Revenue, Total" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r84" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r116", "r488", "r498" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r116", "r488" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r116", "r488", "r498", "r500" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current income tax expense (benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r116", "r488", "r498" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r210", "r223", "r224", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss", "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance", "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total", "verboseLabel": "Allowance for losses on available-for-sale debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities, Available-for-sale, Term", "terseLabel": "Securities contractual term" } } }, "localname": "DebtSecuritiesAvailableForSaleTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)", "terseLabel": "Total unrealized gains recorded in accumulated other comprehensive income (loss)", "totalLabel": "Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r116", "r489", "r498" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncome": { "auth_ref": [ "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r103", "r116", "r489", "r498", "r499", "r500" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred income tax expense (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r23", "r24", "r478", "r673", "r685" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Deferred tax liabilities", "totalLabel": "Deferred Tax Liabilities, Gross, Total" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r464", "r465" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability", "totalLabel": "Deferred Income Tax Liabilities, Net, Total" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred revenue", "totalLabel": "Deferred Revenue, Total" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue, current portion", "totalLabel": "Deferred Revenue, Current, Total" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, noncurrent", "totalLabel": "Deferred Revenue, Noncurrent, Total" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r116", "r489", "r498" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r479" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r486", "r487" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r484", "r486", "r487" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research and development tax credit carryforward" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r486", "r487" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Equity compensations" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r486", "r487" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Reserves and accruals", "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r480" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r465", "r481" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities", "totalLabel": "Deferred Tax Liabilities, Net, Total" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r486", "r487" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": { "auth_ref": [ "r486", "r487" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.", "label": "Deferred Tax Liabilities, Unrealized Gains on Trading Securities", "negatedLabel": "Unrealized gain on investments" } } }, "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities": { "auth_ref": [ "r312", "r333", "r674", "r689" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.", "label": "Liability, Defined Benefit Pension Plan", "terseLabel": "Net liability recognized under pension plans" } } }, "localname": "DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r389" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan, contribution expenses" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Defined contribution plan, company contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Defined contribution plan, employee contribution" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r103", "r181" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "verboseLabel": "Depreciation and amortization expenses" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r55", "r58", "r59", "r556", "r646" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Estimated fair value of the derivative liability", "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r555" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Change in estimated fair value of derivative liability", "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesEmbeddedDerivatives": { "auth_ref": [ "r552", "r553", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.", "label": "Derivatives, Embedded Derivatives [Policy Text Block]", "terseLabel": "Embedded Derivatives" } } }, "localname": "DerivativesEmbeddedDerivatives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technologies" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Awards" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwards" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r82", "r131", "r132", "r133", "r134", "r135", "r140", "r142", "r157", "r158", "r159", "r163", "r164", "r571", "r572", "r680", "r700" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Net income (loss) per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r82", "r131", "r132", "r133", "r134", "r135", "r142", "r157", "r158", "r159", "r163", "r164", "r571", "r572", "r680", "r700" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Net income (loss) per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r160", "r161", "r162", "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShare1" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r467" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r118", "r467", "r502" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r467", "r502" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Changes in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r467", "r502" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign tax at less than federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r467", "r502" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r467", "r502" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "terseLabel": "Prior year tax rate adjustment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r467", "r502" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r467", "r502" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedLabel": "Research and development tax credit", "terseLabel": "Research and development tax credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "auth_ref": [ "r557" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.", "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded derivative liability", "verboseLabel": "Estimated fair value of embedded derivative" } } }, "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure embedded derivative liability.", "label": "Embedded Derivative Liability, Measurement Input", "terseLabel": "Fair value contingent consideration measurement input" } } }, "localname": "EmbeddedDerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Estimated weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r444" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to unvested restricted stock" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r444" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unamortized stock-based compensation expense related to stock option" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Option", "verboseLabel": "Options Issued and Outstanding" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r75", "r76", "r77", "r124", "r125", "r126", "r128", "r136", "r138", "r167", "r219", "r296", "r298", "r451", "r452", "r453", "r494", "r495", "r570", "r594", "r595", "r596", "r597", "r598", "r599", "r712", "r713", "r714", "r761" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r212", "r702" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "terseLabel": "Change in fair value of equity investments", "totalLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss), Total" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r103", "r288" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Change in estimated fair value of convertible preferred stock warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r573", "r574", "r575", "r580" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Estimated Fair Value of Significant Unobservable Inputs" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r573", "r574" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r573", "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r284", "r286", "r287", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r383", "r574", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r579", "r580" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r284", "r335", "r337", "r342", "r383", "r574", "r637" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r284", "r286", "r287", "r335", "r337", "r342", "r383", "r574", "r638" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r284", "r286", "r287", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r383", "r574", "r639" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r578", "r580" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r578", "r580" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Estimated Fair Value of Financial Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "terseLabel": "Changes in fair value", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r578" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at December 31, 2021", "periodStartLabel": "Balance at December 31, 2020" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r284", "r286", "r287", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r383", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r605" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current portion of finance lease obligation", "verboseLabel": "Financing lease obligation, current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r605" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term portion of finance lease obligation" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r607", "r614" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Payment of principal on financing lease obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": { "auth_ref": [ "r538", "r722" ], "lang": { "en-us": { "role": { "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.", "label": "Financial Support to Nonconsolidated Legal Entity [Axis]", "terseLabel": "Financial Support to Nonconsolidated Legal Entity" } } }, "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": { "auth_ref": [ "r538", "r722" ], "lang": { "en-us": { "role": { "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.", "label": "Financial Support to Nonconsolidated Legal Entity [Domain]", "terseLabel": "Financial Support to Nonconsolidated Legal Entity" } } }, "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivableAccruedInterestWriteoff": { "auth_ref": [ "r222" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of writeoff of accrued interest on financing receivable recognized by reversing interest income.", "label": "Financing Receivable, Accrued Interest, Writeoff", "terseLabel": "Write off of accrued interest receivable" } } }, "localname": "FinancingReceivableAccruedInterestWriteoff", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, estimated useful life", "verboseLabel": "Weighted-Average Remaining Useful Life (Years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r242" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r244" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": 0.0, "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r244" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": 4.0, "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r244" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": 3.0, "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r244" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r244" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.", "label": "Finite-Lived Intangible Assets, Amortization Method", "terseLabel": "Finite-lived intangible assets, amortization method description" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r236", "r238", "r242", "r245", "r650", "r654" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r242", "r654" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-lived intangible assets, gross", "totalLabel": "Finite-Lived Intangible Assets, Gross, Total" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r236", "r241" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r242", "r650" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "totalLabel": "Finite-lived intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r104", "r591", "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "terseLabel": "Foreign Currency Transaction Gain Loss Unrealized" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r601" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r603" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "negatedLabel": "Gain from a sublease termination", "terseLabel": "Gain from a sublease termination" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r226", "r228", "r633", "r669" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending Balance", "periodStartLabel": "Goodwill, Beginning Balance", "terseLabel": "Goodwill", "totalLabel": "Goodwill, Total", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Acquired Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r103", "r227", "r229", "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant Revenue [Member]", "verboseLabel": "Grant Member" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r103", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets, excluding goodwill", "totalLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r103", "r246" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "negatedLabel": "Less impairment of intangible assets", "terseLabel": "Impairment of intangible assets", "verboseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r103", "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Indefinite-lived impairment of intangible assets", "verboseLabel": "Impairment of indefinite-lived intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r117", "r501" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r79", "r183", "r191", "r194", "r197", "r199", "r667", "r677", "r682", "r703" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (loss) before provision for income taxes", "totalLabel": "Income (loss) before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r117", "r501" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfLossBeforeProvisionForBenefitFromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r118", "r468", "r476", "r483", "r496", "r503", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r119", "r137", "r138", "r182", "r466", "r497", "r504", "r704" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "negatedTotalLabel": "Provision for income taxes", "terseLabel": "Provision for income taxes", "totalLabel": "Provision for (benefit from) income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r74", "r462", "r463", "r476", "r477", "r482", "r490" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r102" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r102" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Receivable from collaboration" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued liabilities and other long-term liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r102" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Change in deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r102" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": { "auth_ref": [ "r98", "r211" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Increase (Decrease) in Equity Securities, FV-NI", "terseLabel": "Increase Decrease In Equity Securities Fv Ni" } } }, "localname": "IncreaseDecreaseInEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r102", "r614" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r102" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "totalLabel": "Increase (Decrease) in Other Operating Assets, Total" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r102" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": { "auth_ref": [ "r144", "r145", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r159" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares", "terseLabel": "Contingently issuable shares" } } }, "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r143", "r144", "r146", "r159" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Options to purchase common stock", "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived intangible assets IPR&D" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r234", "r240" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r89" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "terseLabel": "Interest income", "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r723", "r725", "r726" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Investment Owned, at Fair Value", "terseLabel": "Investment Owned At Fair Value" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r213", "r701" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r697" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Carrying value of investment at cost", "totalLabel": "Investments, Total" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAgreementsMember": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.", "label": "Lease Agreements [Member]", "terseLabel": "Lease Agreements" } } }, "localname": "LeaseAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r618", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Total least cost", "totalLabel": "Lease, Cost, Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Lease, term of contract" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Lessee, operating lease, existence of option to extend [true false]" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r619" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r619" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r619" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r619" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r619" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r619" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r619" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r619" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Lessee, operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r115", "r193", "r214", "r269", "r270", "r271", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r542", "r547", "r548", "r582", "r631", "r632" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r35", "r115", "r214", "r582", "r633", "r675", "r693" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r48", "r115", "r214", "r269", "r270", "r271", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r542", "r547", "r548", "r582", "r631", "r632", "r633" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r40" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Long-term investments", "totalLabel": "Long-term Investments, Total" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r9", "r46" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Short-term investments", "totalLabel": "Marketable Securities, Current, Total" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected Stock Price Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Measurement Input Risk Free Interest Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r100" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r100" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r100", "r101", "r104" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r68", "r71", "r77", "r80", "r104", "r115", "r127", "r131", "r132", "r133", "r134", "r137", "r138", "r156", "r183", "r191", "r194", "r197", "r199", "r214", "r269", "r270", "r271", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r572", "r582", "r678", "r698" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations", "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetRentableArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net rentable area for properties owned.", "label": "Net Rentable Area" } } }, "localname": "NetRentableArea", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "NONCASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": { "auth_ref": [ "r107", "r108", "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired", "terseLabel": "Issuance of preferred stock in connection with asset acquisition", "totalLabel": "Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r88" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r183", "r191", "r194", "r197", "r199" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r611", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r605" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r605" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 }, "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r605" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r608", "r614" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating lease liabilities", "verboseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r604" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": -1.0 }, "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating right-of-use assets", "verboseLabel": "Operating ROU assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r617", "r620" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r616", "r620" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r551" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r15", "r16", "r47" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r21", "r670", "r686" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets", "totalLabel": "Other Assets, Total" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r69", "r72", "r539", "r540", "r545" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": { "auth_ref": [ "r63", "r66", "r67", "r354" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax", "negatedLabel": "Amortization of actuarial loss" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r61", "r63" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 0.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gains (losses) on investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other Expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net", "totalLabel": "Other Nonoperating Income (Expense), Total" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Offering expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r93", "r520" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Business acquisition, cash consideration paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r95" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments", "totalLabel": "Payments to Acquire Investments, Total" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r94" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r334", "r336", "r342", "r360", "r362", "r363", "r364", "r365", "r366", "r383", "r386", "r388", "r389", "r410" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Defined Contribution Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": { "auth_ref": [ "r367", "r387", "r389", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]", "terseLabel": "Pension Benefits" } } }, "localname": "PensionAndOtherPostretirementPlansPensionsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r361", "r364", "r368", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r389", "r390", "r405", "r406", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plan" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r414", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r27", "r290" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r27", "r290" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r27", "r633" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2021 and 2020, respectively; no shares issued and outstanding as of December 31, 2021 and 2020", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r37", "r38" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses And Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Net proceeds after deducting underwriting discounts, commissions and offering expenses" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r96" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock in connection with a collaboration agreements" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r96" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance cost", "verboseLabel": "Net proceeds from sale of convertible preferred stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r92" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities of investments", "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": { "auth_ref": [ "r91" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sale of machinery and equipment.", "label": "Proceeds from Sale of Machinery and Equipment", "terseLabel": "Proceeds from disposal of an asset held for sale" } } }, "localname": "ProceedsFromSaleOfMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r96", "r446" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r96" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r68", "r71", "r77", "r99", "r115", "r127", "r137", "r138", "r183", "r191", "r194", "r197", "r199", "r214", "r269", "r270", "r271", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r539", "r543", "r544", "r549", "r550", "r572", "r582", "r682" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r43", "r251" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Property and equipment, estimated useful lives description" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r42", "r249" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r251", "r633", "r684", "r694" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r41", "r251", "r732", "r733" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r19", "r251" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r249" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r361", "r624", "r625" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r361", "r624", "r628", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r622", "r623", "r625", "r629", "r630" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r460", "r648", "r745" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research Tax Credit Carryforward" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r18", "r105", "r110" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash and cash equivalents, current", "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r12", "r21", "r105", "r110", "r729" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash and cash equivalents, noncurrent", "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashEquivalents": { "auth_ref": [ "r110", "r668", "r690", "r728", "r730" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash Equivalents", "terseLabel": "Restricted cash equivalents", "totalLabel": "Restricted Cash Equivalents, Total" } } }, "localname": "RestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock", "verboseLabel": "Restricted Shares Subject to Future Vesting" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r31", "r298", "r454", "r633", "r692", "r716", "r721" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r124", "r125", "r126", "r128", "r136", "r138", "r219", "r451", "r452", "r453", "r494", "r495", "r570", "r712", "r714" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r361", "r364", "r368", "r369", "r370", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]", "terseLabel": "Retirement Plan Name" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r361", "r364", "r368", "r369", "r370", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r409" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]", "terseLabel": "Retirement Plan Name" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r361", "r364", "r368", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r389", "r390", "r391", "r392", "r393", "r394", "r405", "r406", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r361", "r364", "r368", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r389", "r390", "r391", "r392", "r393", "r394", "r405", "r406", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r179", "r180", "r190", "r195", "r196", "r200", "r201", "r203", "r304", "r305", "r649" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r85", "r272", "r274", "r275", "r279", "r280", "r281", "r724" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from Related Parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueNotFromContractWithCustomer": { "auth_ref": [ "r78" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606.", "label": "Revenue Not from Contract with Customer", "terseLabel": "Total revenues", "verboseLabel": "Revenue from grants" } } }, "localname": "RevenueNotFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r112", "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r78", "r115", "r179", "r180", "r190", "r195", "r196", "r200", "r201", "r203", "r214", "r269", "r270", "r271", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r582", "r682" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenue", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r615", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets in exchange for operating lease liabilities", "verboseLabel": "Operating lease liabilities obtained in exchange of right-of-use asset" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesWagesAndOfficersCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]" } } }, "localname": "SalariesWagesAndOfficersCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Common stock price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule Of Acquired Finite Lived Intangible Asset By Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r367", "r368", "r371", "r372", "r383" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Income (loss) Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r236", "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r43", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Selected Quarterly Financial Data" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r626", "r628" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r414", "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r420", "r430", "r433" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Plans Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Employees Stock Purchase Plan" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r475", "r491" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Reconciliation of Liability for Uncertain Tax Positions" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r189", "r201" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expense" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r102" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Options vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on offering date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date", "terseLabel": "Purchase price as percentage of lower of fair market value on offering date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Purchase price as percentage of lower of fair market value on purchase date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of shares, Forfeited", "terseLabel": "Number of shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Shares, Unvested, Ending Balance", "periodStartLabel": "Number of Shares, Unvested, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance", "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Shares, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "verboseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility", "verboseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected stock price volatility,maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected stock price volatility,minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Percentage of employee payroll deduction on earnings", "verboseLabel": "Percentage of employee payroll deduction on earnings, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized to issue under purchase rights granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "verboseLabel": "Aggregate intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Options,Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Options,Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r422", "r445" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options,Outstanding, Ending Balance", "periodStartLabel": "Number of Options,Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r435" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Number of Options,Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price,Vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r433" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of Options,Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price,Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r412", "r418" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share purchase price per share" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period of awards from issuance date" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r437", "r455" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of options (in years)", "verboseLabel": "Expected term of ESPP (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term,Vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term,Vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term,Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price as percentage of lower of fair market value on offering date", "verboseLabel": "Option price as a percentage of estimated fair value on the date of grant" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Convertible preferred stock, shares sold, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r612", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r111", "r123" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r26", "r27", "r28", "r114", "r115", "r142", "r147", "r155", "r157", "r159", "r168", "r169", "r170", "r214", "r269", "r274", "r275", "r276", "r280", "r281", "r290", "r291", "r294", "r295", "r296", "r582", "r754" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r52", "r75", "r76", "r77", "r124", "r125", "r126", "r128", "r136", "r138", "r167", "r219", "r296", "r298", "r451", "r452", "r453", "r494", "r495", "r570", "r594", "r595", "r596", "r597", "r598", "r599", "r712", "r713", "r714", "r761" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r124", "r125", "r126", "r167", "r649" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsTables", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r51", "r285", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock into common stock (in shares)", "verboseLabel": "Number of convertible preferred stock converted to shares of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r27", "r28", "r296", "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Share issued under plan", "verboseLabel": "Issuance of common stock under employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r27", "r28", "r296", "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock (in shares)", "verboseLabel": "Issuance of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r296", "r298" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted common stock (in shares)", "verboseLabel": "Vesting of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r27", "r28", "r296", "r298", "r423" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Options,Exercised", "terseLabel": "Exercise of stock option (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r52", "r296", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock into common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r27", "r28", "r296", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r27", "r28", "r296", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Net proceeds from IPO", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r27", "r28", "r296", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r52", "r296", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r28", "r33", "r34", "r115", "r207", "r214", "r582", "r633" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split, conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split, description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r600", "r635" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "verboseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r600", "r635" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r600", "r635" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r600", "r635" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r634", "r636" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEvent1" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SwissFederalTaxAdministrationFTAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Switzerland.", "label": "Swiss Federal Tax Administration (FTA) [Member]", "terseLabel": "Swiss Federal Tax Administration (FTA)" } } }, "localname": "SwissFederalTaxAdministrationFTAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r17", "r289" ], "lang": { "en-us": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]", "terseLabel": "Temporary Equity By Class Of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r269", "r274", "r275", "r276", "r280", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity Disclosure [Abstract]" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]", "terseLabel": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Preferred stock shares issued", "verboseLabel": "Issuance of convertible preferred stock, net of issuance cost (in Shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Convertible preferred stock, shares outstanding", "verboseLabel": "Outstanding convertible preferred stock (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of convertible preferred stock, net of issuance cost" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TenantImprovements": { "auth_ref": [ "r696" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.", "label": "Tenant Improvements", "terseLabel": "Tenant improvement allowance" } } }, "localname": "TenantImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r127", "r128", "r129", "r130", "r139", "r208", "r209", "r216", "r217", "r218", "r219", "r220", "r221", "r268", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r492", "r493", "r494", "r495", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r621", "r651", "r652", "r653", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r757", "r758", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r120", "r335", "r383", "r683" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Government Treasuries" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r461", "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Gross unrecognized tax benefits at December 31", "periodStartLabel": "Gross unrecognized tax benefits at January 1", "terseLabel": "Unrecognized tax benefit" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r472" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reduction for tax positions taken in the prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r469" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Interest and penalties accrued related to uncertain tax positions", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Interest and penalties expense related to uncertain tax positions", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r473" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Addition for tax positions taken in current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r472" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Addition for tax positions taken in the prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits, if recognized, would reduce effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r171", "r172", "r173", "r174", "r175", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r481" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase/decrease in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r613", "r620" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant", "verboseLabel": "Warrants to Purchase Convertible Preferred Stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants and Rights Outstanding, Maturity Date", "terseLabel": "Warrant, expiration date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r141", "r159" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r140", "r159" ], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "vir_AccruedLiabilitiesAndOtherLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities And Other Liabilities.", "label": "Accrued Liabilities And Other Liabilities [Member]", "terseLabel": "Accrued Liabilities And Other Liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advanced proceeds applied to convertible preferred stock issuance.", "label": "Advanced Proceeds Applied To Convertible Preferred Stock Issuance", "terseLabel": "Advanced proceeds applied to convertible preferred stock issuance" } } }, "localname": "AdvancedProceedsAppliedToConvertiblePreferredStockIssuance", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_AlnylamAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alnylam agreement.", "label": "Alnylam Agreement [Member]", "terseLabel": "Alnylam Agreement" } } }, "localname": "AlnylamAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_AlnylamPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alnylam Pharmaceuticals, Inc.", "label": "Alnylam Pharmaceuticals Inc [Member]", "terseLabel": "Alnylam Pharmaceuticals Inc" } } }, "localname": "AlnylamPharmaceuticalsIncMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_AnnualLicenseMaintenanceFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License maintenance fees required to pay annually.", "label": "Annual License Maintenance Fees" } } }, "localname": "AnnualLicenseMaintenanceFees", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_AnotherProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Another product.", "label": "Another Product [Member]", "terseLabel": "Another Product" } } }, "localname": "AnotherProductMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_AntibodyLicenseTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Transaction price for the Antibody License under the collaboration agreement", "label": "Antibody License Transaction Price", "terseLabel": "Antibody license transaction price" } } }, "localname": "AntibodyLicenseTransactionPrice", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_AntibodyProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Antibody Program.", "label": "Antibody Program [Member]", "terseLabel": "Antibody Program" } } }, "localname": "AntibodyProgramMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_AssetAcquisitionMilestoneAchieved": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset acquisition milestone achieved during the reporting period.", "label": "Asset Acquisition Milestone Achieved", "terseLabel": "Asset acquisition milestone achieved" } } }, "localname": "AssetAcquisitionMilestoneAchieved", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_AssetAcquisitionMilestonePaymentAggregate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Asset Acquisition Milestone Payment Aggregate", "terseLabel": "Milestone payments aggregate amount payable, maximum" } } }, "localname": "AssetAcquisitionMilestonePaymentAggregate", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset acquisition number of milestones achieved related to contingent consideration.", "label": "Asset Acquisition Number Of Milestones Achieved Related To Contingent Consideration", "terseLabel": "Number of milestones achieved" } } }, "localname": "AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_BillAndMelindaGatesFoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bill & Melinda Gates Foundation.", "label": "Bill And Melinda Gates Foundation [Member]", "terseLabel": "Bill & Melinda Gates Foundation" } } }, "localname": "BillAndMelindaGatesFoundationMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_BillMelindaGatesFoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bill & Melinda Gates Foundation.", "label": "Bill & Melinda Gates Foundation [Member]", "terseLabel": "Bill & Melinda Gates Foundation" } } }, "localname": "BillMelindaGatesFoundationMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_BiologicalMaterialsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biological materials.", "label": "Biological Materials [Member]", "terseLabel": "Biological Materials" } } }, "localname": "BiologicalMaterialsMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_BriiAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brii Agreement.", "label": "Brii Agreement [Member]", "terseLabel": "Brii Agreement" } } }, "localname": "BriiAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_BriiBioParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brii Bio Parent.", "label": "Brii Bio Parent [Member]", "terseLabel": "Brii Bio Parent" } } }, "localname": "BriiBioParentMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_BriiBiosciencesOffshoreLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brii Biosciences Offshore Limited.", "label": "Brii Biosciences Offshore Limited [Member]", "terseLabel": "Brii Bio" } } }, "localname": "BriiBiosciencesOffshoreLimitedMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition number of milestones achieved related to contingent consideration.", "label": "Business Acquisition Number Of Milestones Achieved Related To Contingent Consideration", "terseLabel": "Number of milestones achieved" } } }, "localname": "BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisition number of specified clinical milestones achieved.", "label": "Business Acquisition Number Of Specified Clinical Milestones Achieved", "terseLabel": "Number of specified clinical milestones achieved" } } }, "localname": "BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_BusinessAgreementEquityInvestmentCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business agreement equity investment commitment.", "label": "Business Agreement Equity Investment Commitment", "terseLabel": "Business agreement equity investment commitment." } } }, "localname": "BusinessAgreementEquityInvestmentCommitment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_BusinessAgreementGrantAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business agreement grant amount.", "label": "Business Agreement Grant Amount", "terseLabel": "Business agreement grant amount" } } }, "localname": "BusinessAgreementGrantAmount", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combinations additional consideration payable upon achievement of specified events.", "label": "Business Combinations Additional Consideration Payable Upon Achievement Of Specified Events", "terseLabel": "Additional consideration payable upon achievement of specified milestone events" } } }, "localname": "BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents and short-term investments, excluding equity investment.", "label": "Cash Cash Equivalents And Short Term Investments Excluding Equity Investment", "terseLabel": "Cash, cash equivalents and short-term investments, excluding equity investment" } } }, "localname": "CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_CashGrantAwarded": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash grant awarded.", "label": "Cash Grant Awarded", "terseLabel": "Business agreement grant amount" } } }, "localname": "CashGrantAwarded", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid in lieu of fractional shares in reverse split of common stock", "label": "Cash Paid In Lieu Of Fractional Shares In Reverse Split Of Common Stock", "negatedLabel": "Cash paid in lieu of fractional shares related to reverse stock split" } } }, "localname": "CashPaidInLieuOfFractionalSharesInReverseSplitOfCommonStock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_ClinicalAndRegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical and regulatory milestones [Member]", "label": "Clinical And Regulatory Milestones [Member]", "terseLabel": "Clinical and Regulatory Milestones" } } }, "localname": "ClinicalAndRegulatoryMilestonesMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "vir_ClinicalDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical Development [Member]", "label": "Clinical Development [Member]", "terseLabel": "Clinical Development" } } }, "localname": "ClinicalDevelopmentMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_CollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration agreement.", "label": "Collaboration Agreement [Member]", "terseLabel": "Collaboration Agreement" } } }, "localname": "CollaborationAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration agreement, number of separate programs agreed to collaborate.", "label": "Collaboration Agreement Number Of Separate Programs Agreed To Collaborate", "terseLabel": "Number of separate programs" } } }, "localname": "CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_CollaborationAgreementNumberOfUnitsOfAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration agreement, number of units of account.", "label": "Collaboration Agreement Number Of Units Of Account", "terseLabel": "Number of units of account" } } }, "localname": "CollaborationAgreementNumberOfUnitsOfAccount", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_CollaborationAgreementRelatedCostsAndExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs and expenses for the period incurred under the collaboration agreements.", "label": "Collaboration Agreement Related Costs And Expenses", "terseLabel": "Expenses incurred under agreement" } } }, "localname": "CollaborationAgreementRelatedCostsAndExpenses", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_CollaborationAgreementTerminationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration agreement termination description.", "label": "Collaboration Agreement Termination Description", "terseLabel": "Termination description" } } }, "localname": "CollaborationAgreementTerminationDescription", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_CollaborationAgreementTransactionPriceConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaboration agreement transaction price consideration.", "label": "Collaboration Agreement Transaction Price Consideration", "terseLabel": "Collaboration Agreement Transaction Price Consideration" } } }, "localname": "CollaborationAgreementTransactionPriceConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_CollaborationAgreementTransactionPriceUpfrontFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payment received under the Collaboration agreement, which represents part of the transaction price.", "label": "Collaboration Agreement Transaction Price Upfront Fee", "verboseLabel": "Upfront fee" } } }, "localname": "CollaborationAgreementTransactionPriceUpfrontFee", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_CollaborationRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration revenue.", "label": "Collaboration Revenue [Member]", "terseLabel": "Collaboration Revenue [Member]" } } }, "localname": "CollaborationRevenueMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "vir_CollaborationTypeAndPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration Type and Programs", "label": "Collaboration Type and Programs", "terseLabel": "Collaboration type and program" } } }, "localname": "CollaborationTypeAndPrograms", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_CommercialMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial milestones.", "label": "Commercial Milestones [Member]", "terseLabel": "Commercial Milestones" } } }, "localname": "CommercialMilestonesMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "vir_CommonStockIssuanceCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issuance cost.", "label": "Common Stock Issuance Cost", "terseLabel": "Common stock issuance cost" } } }, "localname": "CommonStockIssuanceCost", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "vir_CommonStockIssuedInConnectionWithLicenseAgreement": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common stock issued in connection with license agreement.", "label": "Common Stock Issued In Connection With License Agreement", "terseLabel": "Common stock issued in connection with license agreement" } } }, "localname": "CommonStockIssuedInConnectionWithLicenseAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_CommonStockSharesIssuedForMilestonePaymentShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of common shares issued for milestone payment.", "label": "Common stock shares Issued for milestone payment| shares", "terseLabel": "Common stock shares Issued for milestone payment| shares" } } }, "localname": "CommonStockSharesIssuedForMilestonePaymentShares", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration of credit risk credit loss and other risks and uncertainties.", "label": "Concentration Of Credit Risk Credit Loss And Other Risks And Uncertainties Policy [Text Block]", "terseLabel": "Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties" } } }, "localname": "ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vir_ContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration liability", "label": "Contingent Consideration Liability [Member]", "terseLabel": "Contingent Consideration", "verboseLabel": "Contingent Consideration Liability" } } }, "localname": "ContingentConsiderationLiabilityMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "vir_ContractRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue.", "label": "Contract Revenue [Member]", "terseLabel": "Contract Revenue" } } }, "localname": "ContractRevenueMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of preferred stock into common stock upon completion of initial public offering.", "label": "Conversion Of Preferred Stock Into Common Stock Upon Completion Of Initial Public Offering", "terseLabel": "Conversion of preferred stock into common stock upon completion of initial public offering" } } }, "localname": "ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_ConvertiblePreferredStockIssuanceCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock issuance cost.", "label": "Convertible Preferred Stock Issuance Cost", "terseLabel": "Convertible preferred stock, net of issuance cost" } } }, "localname": "ConvertiblePreferredStockIssuanceCost", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "vir_ConvertiblePreferredStockWarrantLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock warrant liability.", "label": "Convertible Preferred Stock Warrant Liability [Abstract]" } } }, "localname": "ConvertiblePreferredStockWarrantLiabilityAbstract", "nsuri": "http://www.vir.bio/20211231", "xbrltype": "stringItemType" }, "vir_ConvertiblePreferredStockWarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock warrant liability.", "label": "Convertible Preferred Stock Warrant Liability [Member]", "verboseLabel": "Warrant to Purchase Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockWarrantLiabilityMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_ConvertiblePreferredStockWarrantLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of key terms of the warrant agreement and valuation assumptions.", "label": "Convertible Preferred Stock Warrant Liability [Text Block]", "terseLabel": "Convertible Preferred Stock Warrant Liability" } } }, "localname": "ConvertiblePreferredStockWarrantLiabilityTextBlock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability" ], "xbrltype": "textBlockItemType" }, "vir_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.", "label": "Deferred Tax Assets Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities in process research and development.", "label": "Deferred Tax Liabilities In Process Research And Development", "negatedLabel": "IPR&D" } } }, "localname": "DeferredTaxLiabilitiesInProcessResearchAndDevelopment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_DeferredTaxLiabilitiesRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities right of use assets.", "label": "Deferred Tax Liabilities Right Of Use Assets", "negatedLabel": "ROU assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_DefinitiveCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Definitive collaboration agreement.", "label": "Definitive Collaboration Agreement [Member]", "terseLabel": "Definitive Collaboration Agreement" } } }, "localname": "DefinitiveCollaborationAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_DeterminedTransactionPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Determined transaction price.", "label": "Determined Transaction Price", "terseLabel": "Determined transaction price" } } }, "localname": "DeterminedTransactionPrice", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_DevelopedTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developed technology.", "label": "Developed Technology [Member]", "terseLabel": "Developed Technology" } } }, "localname": "DevelopedTechnologyMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "vir_DevelopmentAndManufacturingCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development and manufacturing collaboration agreement.", "label": "Development And Manufacturing Collaboration Agreement [Member]", "terseLabel": "Development and Manufacturing Collaboration Agreement" } } }, "localname": "DevelopmentAndManufacturingCollaborationAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_DevelopmentProgramsExercisedByBriiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development Programs Exercised by Brii [Member]", "label": "Development Programs Exercised by Brii [Member]", "terseLabel": "Development Programs Exercised by Brii" } } }, "localname": "DevelopmentProgramsExercisedByBriiMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_DevelopmentProgramsExercisedByVirMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development Programs Exercised by Vir [Member]", "label": "Development Programs Exercised by Vir [Member]", "terseLabel": "Development Programs Exercised by Vir" } } }, "localname": "DevelopmentProgramsExercisedByVirMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_EachInfectiousDiseaseSiRNAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Each infectious disease siRNA.", "label": "Each Infectious Disease Si R N A [Member]", "terseLabel": "Each Infectious Disease siRNA" } } }, "localname": "EachInfectiousDiseaseSiRNAMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation permanent items percent.", "label": "Effective Income Tax Rate Reconciliation Permanent Items Percent", "terseLabel": "Permanent items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentItemsPercent", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "percentItemType" }, "vir_EquityInvestmentCurrent": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Investment Current", "label": "Equity Investment Current", "terseLabel": "Equity Investment Current" } } }, "localname": "EquityInvestmentCurrent", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "vir_EsppDiscountedPurchasePricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ESPP Discounted Purchase Price Percentage", "label": "ESPP Discounted Purchase Price Percentage", "terseLabel": "ESPP discounted purchase price percentage" } } }, "localname": "EsppDiscountedPurchasePricePercentage", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_EstimatedSharesEmployeeStockPurchasePlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated Shares Employee Stock Purchase Plans", "label": "Estimated Shares Employee Stock Purchase Plans", "terseLabel": "Estimated shares to be issued under plan" } } }, "localname": "EstimatedSharesEmployeeStockPurchasePlans", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vir_EstimatedSharesIssuableUnderTheESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated Shares Issuable Under the E S P P [Member]", "label": "Estimated Shares Issuable Under the E S P P [Member]", "terseLabel": "Estimated Shares Issuable Under The E S P P [Member]" } } }, "localname": "EstimatedSharesIssuableUnderTheESPPMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "domainItemType" }, "vir_ExcessFundsPayableUnderGrantAgreementsCurrent": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess funds payable under grant agreements current.", "label": "Excess Funds Payable Under Grant Agreements Current", "terseLabel": "Excess funds payable under grant agreements" } } }, "localname": "ExcessFundsPayableUnderGrantAgreementsCurrent", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_ExecutiveOfficerAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive officer and director.", "label": "Executive Officer And Director [Member]", "terseLabel": "Executive Officer and Director" } } }, "localname": "ExecutiveOfficerAndDirectorMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_FailedSaleLeasebackTransactionProceedsFinancingActivities": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow received in a failed sale-leaseback recognized in financing activities.", "label": "Failed Sale Leaseback Transaction Proceeds Financing Activities", "terseLabel": "Proceeds received from financing lease obligation" } } }, "localname": "FailedSaleLeasebackTransactionProceedsFinancingActivities", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_FairMarketValueOfCommonStockIssued": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair market value of common stock issued.", "label": "Fair Market Value Of Common Stock Issued", "terseLabel": "Fair market value of the common stock issued" } } }, "localname": "FairMarketValueOfCommonStockIssued", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, reclassification of contingent consideration to accrued liabilities upon achievement of milestone.", "label": "Fair Value Reclassification Of Contingent Consideration To Accrued Liabilities Upon Achievement Of Milestone", "terseLabel": "Payment of contingent consideration upon achievement of the TomegaVax milestone" } } }, "localname": "FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value reclassification of derivative liability to accrued liabilities upon achievement of development milestone.", "label": "Fair Value Reclassification Of Derivative Liability To Accrued Liabilities Upon Achievement Of Development Milestone", "terseLabel": "Reclassification of derivative liability to accrued liabilities upon achievement of development milestone" } } }, "localname": "FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_FinancialAssetsAmortizedCostBasis": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial assets amortized cost basis.", "label": "Financial Assets Amortized Cost Basis", "terseLabel": "Financial Assets, Amortized Cost", "totalLabel": "Financial Assets, Amortized Cost" } } }, "localname": "FinancialAssetsAmortizedCostBasis", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "vir_FinancialAssetsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial assets fair value.", "label": "Financial Assets Fair Value", "terseLabel": "Financial Assets, Aggregate Fair Value" } } }, "localname": "FinancialAssetsFairValue", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "vir_FinancialAssetsGrossUnrealizedHoldingGains": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial assets gross unrealized holding gains.", "label": "Financial Assets Gross Unrealized Holding Gains", "terseLabel": "Financial Assets, Gross Unrealized Holding Gains" } } }, "localname": "FinancialAssetsGrossUnrealizedHoldingGains", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "vir_FinancialAssetsGrossUnrealizedHoldingLosses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial assets gross unrealized holding losses.", "label": "Financial Assets Gross Unrealized Holding Losses", "negatedLabel": "Financial Assets, Gross Unrealized Holding Losses" } } }, "localname": "FinancialAssetsGrossUnrealizedHoldingLosses", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "vir_FiniteLivedIntangibleAssetsAccumulatedImpairment": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finite lived intangible assets accumulated impairment.", "label": "Finite Lived Intangible Assets Accumulated Impairment", "negatedLabel": "Less impairment of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "vir_FiniteLivedIntangibleAssetsAmortizationExpense": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of total amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in the next five years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpense", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-lived Intangible assets, reclassified from Indefinite-lived.", "label": "Finite Lived Intangible Assets Reclassified From Indefinite Lived", "terseLabel": "Finite-lived intangible asset, reclassified from indefinite-lived asset" } } }, "localname": "FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_FirstAndSecondClosingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First and second closings.", "label": "First And Second Closings [Member]", "terseLabel": "Two Closings" } } }, "localname": "FirstAndSecondClosingsMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_FirstInfectiousDiseaseProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First infectious disease product.", "label": "First Infectious Disease Product [Member]", "terseLabel": "Infectious Disease Product" } } }, "localname": "FirstInfectiousDiseaseProductMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_FirstPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First plan.", "label": "First Plan [Member]", "terseLabel": "First Plan" } } }, "localname": "FirstPlanMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_FirstSiRNAProductHBVMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First SiRNA product HBV.", "label": "First Si R N A Product H B V [Member]", "terseLabel": "First siRNA Product HBV" } } }, "localname": "FirstSiRNAProductHBVMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_FirstSiRNAProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First siRNA product member.", "label": "First Si R N A Product [Member]", "terseLabel": "First siRNA Product HBV" } } }, "localname": "FirstSiRNAProductMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-on offering.", "label": "Follow On Offering [Member]", "terseLabel": "Follow-on Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "vir_FormerBusinessCombinationContingentConsiderationLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of former liability recognized arising from contingent consideration in a business combination.", "label": "Former Business Combination, Contingent Consideration, Liability", "terseLabel": "Estimated fair value of former contingent consideration" } } }, "localname": "FormerBusinessCombinationContingentConsiderationLiability", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_FundsReceivedInAdvance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Funds received in advance.", "label": "Funds Received In Advance", "terseLabel": "Funds received in advance" } } }, "localname": "FundsReceivedInAdvance", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_GlaxoGroupLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glaxo Group Limited.", "label": "Glaxo Group Limited [Member]", "terseLabel": "GGL" } } }, "localname": "GlaxoGroupLimitedMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA.", "label": "Glaxo Smith Kline Intellectual Property Development Limited And Glaxo Smith Kline Biologicals S A [Member]", "terseLabel": "GSK" } } }, "localname": "GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_GlaxoSmithKlineTradingServiceLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glaxo SmithKline Trading Service Limited.", "label": "Glaxo Smith Kline Trading Service Limited [Member]", "terseLabel": "GSKTSL" } } }, "localname": "GlaxoSmithKlineTradingServiceLimitedMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_GlaxoWellcomeUKLimitedAndBeechamSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glaxo Wellcome U K Limited And Beecham S A.", "label": "Glaxo Wellcome U K Limited And Beecham S A [Member]", "terseLabel": "GSK" } } }, "localname": "GlaxoWellcomeUKLimitedAndBeechamSAMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_GrantAgreementAmendedDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant agreement amended date.", "label": "Grant Agreement Amended Date", "verboseLabel": "Grant agreement amended date" } } }, "localname": "GrantAgreementAmendedDate", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "vir_GrantAgreementAmendedExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant agreement amended expiration date.", "label": "Grant Agreement Amended Expiration Date", "terseLabel": "Grant agreement amended expiration date" } } }, "localname": "GrantAgreementAmendedExpirationDate", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "vir_GrantAgreementEffectiveEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant agreement effective end date.", "label": "Grant Agreement Effective End Date", "terseLabel": "Grant agreement effective end date" } } }, "localname": "GrantAgreementEffectiveEndDate", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "vir_GrantAgreementExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The date the grant agreement expires.", "label": "Grant Agreement Expiration Date", "terseLabel": "Grant agreement expiration date" } } }, "localname": "GrantAgreementExpirationDate", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "vir_GrantAgreementExpirationDateBeforeAmendment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant agreement expiration date before amendment.", "label": "Grant Agreement Expiration Date Before Amendment", "terseLabel": "Grant agreement expiration date before amendment" } } }, "localname": "GrantAgreementExpirationDateBeforeAmendment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "vir_GrantAgreementsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant agreements disclosure.", "label": "Grant Agreements Disclosure [Text Block]", "terseLabel": "Grant Agreements" } } }, "localname": "GrantAgreementsDisclosureTextBlock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreements" ], "xbrltype": "textBlockItemType" }, "vir_GrantAwardedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Grant awarded amount.", "label": "Grant Awarded Amount", "terseLabel": "Grant awarded amount" } } }, "localname": "GrantAwardedAmount", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_GrantAwardedAmountMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum grant awarded amount.", "label": "Grant Awarded Amount Maximum", "terseLabel": "Grant awarded amount. maximum" } } }, "localname": "GrantAwardedAmountMaximum", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_GrantsAgreementAmendedDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grants Agreement Amended Date", "label": "Grants Agreement Amended Date" } } }, "localname": "GrantsAgreementAmendedDate", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "vir_HBVProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HBV program.", "label": "H B V Program [Member]", "terseLabel": "HBV Program" } } }, "localname": "HBVProgramMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_HcmvVaccinePlatformGrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hcmv Vaccine Platform Grant [Member].", "label": "Hcmv Vaccine Platform Grant [Member]", "terseLabel": "HCMV-Vaccine Platform Grant" } } }, "localname": "HcmvVaccinePlatformGrantMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_HepatitisBVirusProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hepatitis B Virus Product Member.", "label": "Hepatitis B Virus Product [Member]", "terseLabel": "HBV product" } } }, "localname": "HepatitisBVirusProductMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_HumabsBiomedSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Humabs Biomed SA.", "label": "Humabs Biomed S A [Member]", "terseLabel": "Humabs", "verboseLabel": "Humabs IP Transfer" } } }, "localname": "HumabsBiomedSAMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "domainItemType" }, "vir_HumanImmunodeficiencyVirusGrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Human immunodeficiency virus grant.", "label": "Human Immunodeficiency Virus Grant [Member]", "terseLabel": "Human Immunodeficiency Virus (\"HIV\") Grant" } } }, "localname": "HumanImmunodeficiencyVirusGrantMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes line items.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes table.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in payment of contingent consideration in excess of acquisition date fair value.", "label": "Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value", "terseLabel": "Payment of contingent consideration in excess of acquisition date fair value" } } }, "localname": "IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_IncreaseDecreaseInResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in research And development expense.", "label": "Increase Decrease In Research And Development Expense", "terseLabel": "Research and development expense", "verboseLabel": "Increase (decrease) in research and development expense" } } }, "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.", "label": "Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting", "terseLabel": "Restricted shares subject to future vesting" } } }, "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "vir_InfectiousDiseaseProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Infectious Disease Product [Member]", "label": "Infectious Disease Product [Member]" } } }, "localname": "InfectiousDiseaseProductMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_InfluenzaAAndHBVResearchProgramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Influenza A and HBV research programs member.", "label": "Influenza A And H B V Research Programs [Member]", "terseLabel": "Influenza A and HBV Research Programs" } } }, "localname": "InfluenzaAAndHBVResearchProgramsMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_InfluenzaAAndInfluenzaBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Influenza A and Influenza B member.", "label": "Influenza A And Influenza B [Member]", "terseLabel": "Influenza A and Influenza B" } } }, "localname": "InfluenzaAAndInfluenzaBMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_InfluenzaAResearchProgramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Influenza A research programs.", "label": "Influenza A Research Programs [Member]", "terseLabel": "Influenza A Research Programs" } } }, "localname": "InfluenzaAResearchProgramsMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_InitialFairValueOfDerivativeLiability": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial fair value of derivative liability.", "label": "Initial Fair Value Of Derivative Liability", "terseLabel": "Initial fair value of derivative liability" } } }, "localname": "InitialFairValueOfDerivativeLiability", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_InitialPublicOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial public offering costs.", "label": "Initial Public Offering Costs", "terseLabel": "Initial public offering costs" } } }, "localname": "InitialPublicOfferingCosts", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "vir_IssuanceOfCommonStockToSettleAContingentConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock to settle a contingent consideration", "label": "Issuance of common stock to settle a contingent consideration", "terseLabel": "Issuance of common stock to settle a contingent consideration" } } }, "localname": "IssuanceOfCommonStockToSettleAContingentConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "vir_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "vir_LeaseArrangementContractualExpirationBeginningYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease arrangement, contractual expiration beginning year.", "label": "Lease Arrangement Contractual Expiration Beginning Year", "terseLabel": "Lease arrangement, contractual expiration period, beginning year" } } }, "localname": "LeaseArrangementContractualExpirationBeginningYear", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "vir_LeaseArrangementContractualExpirationEndingYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease arrangement, contractual expiration ending year.", "label": "Lease Arrangement Contractual Expiration Ending Year", "terseLabel": "Lease arrangement, contractual expiration period, ending year" } } }, "localname": "LeaseArrangementContractualExpirationEndingYear", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability net tenant improvement allowance yet to be received.", "label": "Lessee Operating Lease Liability Net Tenant Improvement Allowance Yet To Be Received", "negatedLabel": "Less: net tenant improvement allowance yet to be received" } } }, "localname": "LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_LetterAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Letter agreement.", "label": "Letter Agreement [Member]", "terseLabel": "TomegaVax Letter Agreement", "verboseLabel": "Letter Agreement Member" } } }, "localname": "LetterAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_LicenseAgreementUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License agreement upfront payment.", "label": "License Agreement Upfront Payment", "terseLabel": "License agreement upfront payment" } } }, "localname": "LicenseAgreementUpfrontPayment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumAggregateCommercialSalesMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum aggregate commercial sales milestone payments.", "label": "Maximum Aggregate Commercial Sales Milestone Payments", "terseLabel": "Maximum aggregate commercial sales milestone payments" } } }, "localname": "MaximumAggregateCommercialSalesMilestonePayments", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum aggregate development and regulatory milestone payments.", "label": "Maximum Aggregate Development And Regulatory Milestone Payments", "terseLabel": "Maximum aggregate development and regulatory milestone payments" } } }, "localname": "MaximumAggregateDevelopmentAndRegulatoryMilestonePayments", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum aggregate milestone payment for achievement of specified milestones, including development, regulatory and commercial.", "label": "Maximum aggregate milestone payment for achievement of specified milestones" } } }, "localname": "MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumAggregateMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum aggregate milestone payments.", "label": "Maximum Aggregate Milestone Payments", "terseLabel": "Maximum aggregate milestone payments" } } }, "localname": "MaximumAggregateMilestonePayments", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumAggregateSalesMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum aggregate milestone payment for achievement of specified annual net sales", "label": "Maximum Aggregate Sales Milestone Payment", "terseLabel": "Maximum aggregate sales milestone payment" } } }, "localname": "MaximumAggregateSalesMilestonePayment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumAggregateSalesMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum aggregate sales milestone payments.", "label": "Maximum Aggregate Sales Milestone Payments", "terseLabel": "Maximum aggregate sales milestone payments" } } }, "localname": "MaximumAggregateSalesMilestonePayments", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum milestone payment for achievement of specified development and regulatory.", "label": "Maximum Milestone Payment For Achievement Of Specified Development And Regulatory", "terseLabel": "Maximum milestone payment for achievement of specified development and regulatory" } } }, "localname": "MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum Number of Development Program Granted from Counterparty", "label": "Maximum Number of Development Program Granted from Counterparty", "terseLabel": "Maximum number of development program granted from Brii to Vir | Program" } } }, "localname": "MaximumNumberOfDevelopmentProgramGrantedFromCounterparty", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum Number of Development Program Granted to Counterparty", "label": "Maximum Number of Development Program Granted to Counterparty", "terseLabel": "Maximum number of development program granted from Vir to Brii | Program" } } }, "localname": "MaximumNumberOfDevelopmentProgramGrantedToCounterparty", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of products covered against milestone payment.", "label": "Maximum Number of Products Covered Against Milestone Payment", "terseLabel": "Maximum number of products covered against milestone payment" } } }, "localname": "MaximumNumberOfProductsCoveredAgainstMilestonePayment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of right to perform details in connection with antibody product.", "label": "Maximum Percentage Of Right To Perform Details In Connection With Antibody Product", "terseLabel": "Maximum percentage of right to perform details in connection with antibody product" } } }, "localname": "MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_MaximumSalesMilestonToPay": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of proceeds to pay upon achievement of sales milestone", "label": "Maximum Sales Mileston To Pay", "terseLabel": "Maximum sales milestone to pay" } } }, "localname": "MaximumSalesMilestonToPay", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumSalesMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum milestone payment for achievement of specified annual net sales.", "label": "Maximum Sales Milestone Payment", "terseLabel": "Maximum sales milestone payment" } } }, "localname": "MaximumSalesMilestonePayment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MaximumSharesToBeIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum shares to be issued.", "label": "Maximum Shares To Be Issued", "terseLabel": "Maximum shares to be issued" } } }, "localname": "MaximumSharesToBeIssued", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum term of offering period specified under plan.", "label": "Maximum Term Of Offering Period Specified Under Plan", "terseLabel": "Maximum term of offering period specified under plan" } } }, "localname": "MaximumTermOfOfferingPeriodSpecifiedUnderPlan", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_MeasurementInputExpectedRevenueVolatilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input expected revenue volatility.", "label": "Measurement Input Expected Revenue Volatility [Member]", "terseLabel": "Measurement Input Expected Revenue Volatility" } } }, "localname": "MeasurementInputExpectedRevenueVolatilityMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "vir_MeasurementInputExpectedVolatilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input expected volatility.", "label": "Measurement Input Expected Volatility [Member]", "terseLabel": "Measurement Input Expected Volatility" } } }, "localname": "MeasurementInputExpectedVolatilityMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "vir_MeasurementInputProbabilityRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input, probability rate.", "label": "Measurement Input Probability Rate [Member]", "terseLabel": "Probability of Achievement" } } }, "localname": "MeasurementInputProbabilityRateMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "vir_MedImmuneAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MedImmune agreement.", "label": "Med Immune Agreement [Member]", "terseLabel": "MedImmune Agreement" } } }, "localname": "MedImmuneAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_MedImmuneLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MedImmune, limited liability company.", "label": "Med Immune Limited Liability Company [Member]", "terseLabel": "MedImmune" } } }, "localname": "MedImmuneLimitedLiabilityCompanyMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_MilestonePayable": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payable.", "label": "Milestone Payable", "terseLabel": "Milestone payable" } } }, "localname": "MilestonePayable", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_MilestonePaymentDueToCompany": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payment due to company under grant agreement.", "label": "Milestone Payment Due To Company", "terseLabel": "Milestone payment due to Vir" } } }, "localname": "MilestonePaymentDueToCompany", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MilestonePaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment received.", "label": "Milestone Payment Received", "terseLabel": "Milestone payment received" } } }, "localname": "MilestonePaymentReceived", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MilestonePaymentsPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payments paid.", "label": "Milestone Payments Paid", "terseLabel": "Milestone payments paid" } } }, "localname": "MilestonePaymentsPaid", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_MilestonePaymentsRelatedTermsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone payments related terms description.", "label": "Milestone Payments Related Terms Description", "terseLabel": "Milestone payments related terms" } } }, "localname": "MilestonePaymentsRelatedTermsDescription", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum common stock conversion price for milestone payments consideration.", "label": "Minimum Common Stock Conversion Price For Milestone Payments Consideration", "terseLabel": "Minimum common stock conversion price for milestone payments consideration" } } }, "localname": "MinimumCommonStockConversionPriceForMilestonePaymentsConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "vir_MinimumCommonStockPriceForMilestonePaymentsConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum common stock price that triggers milestone payment.", "label": "Minimum Common Stock Price For Milestone Payments Consideration", "terseLabel": "Minimum common stock price for milestone payments consideration" } } }, "localname": "MinimumCommonStockPriceForMilestonePaymentsConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "vir_NationalInstitutesOfHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "National institutes of health.", "label": "National Institutes Of Health [Member]", "terseLabel": "National Institutes of Health" } } }, "localname": "NationalInstitutesOfHealthMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_NetProceedsFromIssuanceSecondaryPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's follow on offering of stock to the public, net of commissions and expenses.", "label": "Net proceeds From Issuance Secondary Public Offering", "terseLabel": "Net proceeds from issuance secondary public offering" } } }, "localname": "NetProceedsFromIssuanceSecondaryPublicOffering", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_NonCashCommonStockIssuedForContingentConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash common stock issued for contingent consideration.", "label": "Non Cash Common Stock Issued For Contingent Consideration", "terseLabel": "Common stock issued for payment of contingent consideration" } } }, "localname": "NonCashCommonStockIssuedForContingentConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash lease expense.", "label": "Noncash Lease Expense", "terseLabel": "Noncash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_NumberOfAntibodiesToDevelop": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of antibodies to develop.", "label": "Number of Antibodies to Develop", "verboseLabel": "Number of antibodies to develop" } } }, "localname": "NumberOfAntibodiesToDevelop", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_NumberOfClassOfStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of class of stock.", "label": "Number of Class of Stock", "terseLabel": "Number of class of stock" } } }, "localname": "NumberOfClassOfStock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of years conduct certain research and development activities under mutually agreed development plans.", "label": "Number Of Years Conduct Certain Research And Development Activities Under Mutually Agreed Development Plans", "terseLabel": "Number of years conduct certain research and development activities under mutually agreed development plans" } } }, "localname": "NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_ObligationToPayCapacityReservation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount obligated to pay for capacity reservation under the agreement.", "label": "Obligation To Pay Capacity Reservation", "terseLabel": "Obligation to pay capacity reservation" } } }, "localname": "ObligationToPayCapacityReservation", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_OfferingPeriodEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Duration of offering period under the Plan.", "label": "Offering Period Employee Stock Purchase Plan", "terseLabel": "Offering period" } } }, "localname": "OfferingPeriodEmployeeStockPurchasePlan", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_OperatingAndFinanceRentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating and finance rent expense.", "label": "Operating And Finance Rent Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingAndFinanceRentExpense", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_OperatingLeaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease.", "label": "Operating Lease [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseAbstract", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "vir_OperatingLeaseIncentiveOverLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Incentive Over Lease Liabilities", "label": "Operating Lease Incentive Over Lease Liabilities", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "OperatingLeaseIncentiveOverLeaseLiabilities", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" ], "xbrltype": "monetaryItemType" }, "vir_OperatingLeaseOtherInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease other information.", "label": "Operating Lease Other Information [Abstract]", "terseLabel": "Other Information" } } }, "localname": "OperatingLeaseOtherInformationAbstract", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "vir_OperatingLossCarryforwardsExpirationBeginningYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards expiration beginning year.", "label": "Operating Loss Carryforwards Expiration Beginning Year", "verboseLabel": "Net operating loss carryforwards expiration beginning year" } } }, "localname": "OperatingLossCarryforwardsExpirationBeginningYear", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "vir_OperatingLossCarryforwardsLimitationOnUsePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards limitation on use percentage.", "label": "Operating Loss Carryforwards Limitation On Use Percentage", "terseLabel": "Net operating loss deduction limitation as percentage of taxable income" } } }, "localname": "OperatingLossCarryforwardsLimitationOnUsePercentage", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_OptionExerciseFeeConsiderationToBeReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Option exercise fee consideration to be received.", "label": "Option Exercise Fee Consideration To Be Received", "terseLabel": "Option exercise fee to be received" } } }, "localname": "OptionExerciseFeeConsiderationToBeReceived", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_OptionExerciseFeeHighEndOfTheRange": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the high end of the range of option exercise fee upon exercise of a program.", "label": "Option exercise fee, high end of the range", "terseLabel": "Option exercise fee, high end of the range" } } }, "localname": "OptionExerciseFeeHighEndOfTheRange", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_OptionExerciseFeeLowEndOfTheRange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the low end of the range of option exercise fee upon exercise of a program.", "label": "Option exercise fee, low end of the range", "terseLabel": "Option exercise fee, low end of the range" } } }, "localname": "OptionExerciseFeeLowEndOfTheRange", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_OptionExerciseFeeReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Option exercise fee received.", "label": "Option Exercise Fee Received", "terseLabel": "Option exercise fee received" } } }, "localname": "OptionExerciseFeeReceived", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other comprehensive income loss pension and other postretirement benefit plans adjustment to projected benefit obligations net of tax.", "label": "Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment To Projected Benefit Obligations Net Of Tax", "negatedLabel": "Adjustment to projected benefit obligations, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "vir_PaymentMadeForAssetAcquisitionMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment made for asset acquisition milestone.", "label": "Payment Made For Asset Acquisition Milestone", "terseLabel": "Payment made for asset acquisition milestone" } } }, "localname": "PaymentMadeForAssetAcquisitionMilestone", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_PaymentMadeForBusinessCombinationMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment made for business combination milestone.", "label": "Payment made for business combination milestone", "terseLabel": "Payment made for business combination milestone" } } }, "localname": "PaymentMadeForBusinessCombinationMilestone", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_PaymentOfContingentConsideration": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of contingent consideration.", "label": "Payment Of Contingent Consideration", "negatedLabel": "Payment of contingent consideration" } } }, "localname": "PaymentOfContingentConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_PaymentToCollaboratorResultingFromProgramOptionExercise": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to a collaborator due to a program option exercise under a separate agreement.", "label": "Payment to collaborator resulting from program option exercise", "terseLabel": "Payment to collaborator resulting from program option exercise" } } }, "localname": "PaymentToCollaboratorResultingFromProgramOptionExercise", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_PaymentsOfUnderwritingDiscountsAndCommissions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of underwriting discounts and commissions.", "label": "Payments Of Underwriting Discounts And Commissions", "terseLabel": "Payments of underwriting discounts and commissions" } } }, "localname": "PaymentsOfUnderwritingDiscountsAndCommissions", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_PayrollAndRelatedExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payroll and related expenses current.", "label": "Payroll And Related Expenses Current", "terseLabel": "Payroll and related expenses" } } }, "localname": "PayrollAndRelatedExpensesCurrent", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_PercentageOfAggregateGrossProceedsFromSaleOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of aggregate gross proceeds from sale of shares.", "label": "Percentage Of Aggregate Gross Proceeds From Sale Of Shares", "terseLabel": "Percentage of aggregate gross proceeds from sale of shares" } } }, "localname": "PercentageOfAggregateGrossProceedsFromSaleOfShares", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_PercentageOfCommissionRateFromSaleOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of maximum commission rate, based on aggregate gross proceeds from sale of shares.", "label": "Percentage of commission rate from sale of shares", "terseLabel": "Percentage of commission rate from sale of shares" } } }, "localname": "PercentageOfCommissionRateFromSaleOfShares", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_PercentageOfDevelopmentCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of development costs.", "label": "Percentage Of Development Costs", "terseLabel": "Percentage of development costs" } } }, "localname": "PercentageOfDevelopmentCosts", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_PercentageOfEstimatedBatchProductionFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of estimated batch production fees owed.", "label": "Percentage Of Estimated Batch Production Fees", "terseLabel": "Percentage of estimated batch production fees" } } }, "localname": "PercentageOfEstimatedBatchProductionFees", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_PercentageOfOrdinaryShareEqualToOutstandingShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ordinary share equal to outstanding share.", "label": "Percentage Of Ordinary Share Equal To Outstanding Share", "terseLabel": "Percentage of ordinary share equal to outstanding share" } } }, "localname": "PercentageOfOrdinaryShareEqualToOutstandingShare", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_PercentageOfShareDevelopmentCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of share development costs.", "label": "Percentage Of Share Development Costs", "terseLabel": "Percentage of share development costs" } } }, "localname": "PercentageOfShareDevelopmentCosts", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of upfront payment receivable at effective date of agreement.", "label": "Percentage Of Upfront Payment Receivable At Effective Date Of Agreement", "terseLabel": "Percentage of upfront payment receivable at effective date of agreement" } } }, "localname": "PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of upfront payment receivable at execution date of agreement", "label": "Percentage of upfront payment receivable at execution date of agreement" } } }, "localname": "PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_PreDefinedRegulatoryMilestoneConsiderationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Pre-defined regulatory milestone consideration receivable.", "label": "Pre Defined Regulatory Milestone Consideration Receivable", "terseLabel": "Pre-defined regulatory milestone payment" } } }, "localname": "PreDefinedRegulatoryMilestoneConsiderationReceivable", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_PreliminaryCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preliminary Collaboration Agreement.", "label": "Preliminary Collaboration Agreement [Member]", "terseLabel": "Preliminary Collaboration Agreement" } } }, "localname": "PreliminaryCollaborationAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_PremiumReceivedOnSalePriceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Premium received on sale price of common stock.", "label": "Premium Received On Sale Price Of Common Stock", "terseLabel": "Premium received on sale price of common stock" } } }, "localname": "PremiumReceivedOnSalePriceOfCommonStock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_PresentValueOfOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.", "label": "Present Value Of Operating Lease Liabilities", "terseLabel": "Present value of operating lease liabilities" } } }, "localname": "PresentValueOfOperatingLeaseLiabilities", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance of Common Stock in Connection With Collaboration.", "label": "Proceeds From Issuance of Common Stock in Connection With Collaboration", "terseLabel": "Proceeds from issuance of common stock in connection with a collaboration agreement" } } }, "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_ProceedsFromIssuanceSecondaryPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's follow on offering of stock to the public.", "label": "Proceeds From Issuance Secondary Public Offering", "terseLabel": "Net proceeds after deducting underwriting discounts, commissions and offering expenses" } } }, "localname": "ProceedsFromIssuanceSecondaryPublicOffering", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_ProceedsFromRepaymentOfPromissoryNotes": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from repayment of promissory notes.", "label": "Proceeds From Repayment Of Promissory Notes", "terseLabel": "Proceeds from repayment of promissory notes" } } }, "localname": "ProceedsFromRepaymentOfPromissoryNotes", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_ProfitsAndLossesSharingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Profits and losses sharing percentage.", "label": "Profits And Losses Sharing Percentage", "terseLabel": "Percentage of share Profit and loss" } } }, "localname": "ProfitsAndLossesSharingPercentage", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vir_RangeOfRoyaltyPaymentToBePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of royalty payment to be paid by counterparty.", "label": "Range of Royalty Payment to be Paid", "terseLabel": "Range of royalty payment to be paid" } } }, "localname": "RangeOfRoyaltyPaymentToBePaid", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_RangeOfRoyaltyPaymentToBeReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of royalty payment to be received by the company upon exercised of the development programs by counterparty.", "label": "Range of Royalty Payment to be Received", "terseLabel": "Range of royalty payment to be received" } } }, "localname": "RangeOfRoyaltyPaymentToBeReceived", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of tiered royalties to pay on annual net sales of products.", "label": "Range of Tiered Royalties to Pay to Net Sales of Products", "verboseLabel": "Range of tiered royalties to pay on net sales of products" } } }, "localname": "RangeOfTieredRoyaltiesToPayToNetSalesOfProducts", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of derivative liability to additional paid In capital.", "label": "Reclassification Of Derivative Liability To Additional Paid In Capital", "terseLabel": "Reclassification of derivative liability to addition paid-in-capital" } } }, "localname": "ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification\u200b of derivative liability\u200b to additional paid-\u200bin capital upon achievement of development milestone.", "label": "Reclassification Of Derivative Liability To Additional Paid In Capital Upon Achievement Of Development Milestone", "terseLabel": "Reclassification of derivative liability to additional paid-in capital" } } }, "localname": "ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of preferred stock warrant liability to additional paid-in capital.", "label": "Reclassification Of Preferred Stock Warrant Liability To Additional Paid In Capital", "terseLabel": "Reclassification of preferred stock warrant liability to additional paid-in capital" } } }, "localname": "ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vir_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of warrant liability to additional paid-in capital.", "label": "Reclassification Of Warrant Liability To Additional Paid In Capital", "terseLabel": "Reclassification of warrant liability to additional paid-in capital" } } }, "localname": "ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "vir_ReconciliationOfEffectiveIncomeTaxRateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of effective income tax rate.", "label": "Reconciliation Of Effective Income Tax Rate [Line Items]", "terseLabel": "Reconciliation Of Effective Income Tax Rate [Line Items]" } } }, "localname": "ReconciliationOfEffectiveIncomeTaxRateLineItems", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "stringItemType" }, "vir_ReconciliationOfEffectiveIncomeTaxRateTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reconciliation of effective income tax rate.", "label": "Reconciliation Of Effective Income Tax Rate [Table]", "terseLabel": "Reconciliation Of Effective Income Tax Rate [Table]" } } }, "localname": "ReconciliationOfEffectiveIncomeTaxRateTable", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" ], "xbrltype": "stringItemType" }, "vir_RegulatoryMilestoneAchieved": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Regulatory milestones achieved during the reporting period.", "label": "Regulatory Milestone Achieved", "terseLabel": "Regulatory milestone achieved" } } }, "localname": "RegulatoryMilestoneAchieved", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Regulatory milestone payment on licensed product, high end of the range.", "label": "Regulatory Milestone Payment On Licensed Product High End Of Range", "terseLabel": "Regulatory milestone payment on licensed product, high end of the range" } } }, "localname": "RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory milestone payment on licensed product, low end of the range.", "label": "Regulatory Milestone Payment On Licensed Product Low End Of The Range", "terseLabel": "Regulatory milestone payment on licensed product, low end of the range" } } }, "localname": "RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_RegulatoryMilestonePaymentToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Regulatory milestone payment to be received by the company upon exercised of the development programs by counterparty.", "label": "Regulatory Milestone Payment to be Received", "terseLabel": "Regulatory milestone payment to be received" } } }, "localname": "RegulatoryMilestonePaymentToBeReceived", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_RegulatoryMilestonesAchieved": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Regulatory milestones achieved during the reporting period.", "label": "Regulatory Milestones Achieved", "terseLabel": "Regulatory milestones achieved" } } }, "localname": "RegulatoryMilestonesAchieved", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_ReleaseOfValuationAllowanceDeferredTaxInAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Release of valuation allowance deferred tax in amount.", "label": "Release of Valuation Allowance Deferred Tax In Amount", "terseLabel": "Release of valuation allowance" } } }, "localname": "ReleaseOfValuationAllowanceDeferredTaxInAmount", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the remaining consideration which may be paid.", "label": "Remaining Payment For Asset Acquisition Milestone Aggregate", "terseLabel": "Remaining payment for asset acquisition milestone, maximum" } } }, "localname": "RemainingPaymentForAssetAcquisitionMilestoneAggregate", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_RemainingPaymentMadeForAssetAcquisitionMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remaining payment made for asset acquisition milestone.", "label": "Remaining Payment Made For Asset Acquisition Milestone", "terseLabel": "Remaining payment made for asset acquisition milestone" } } }, "localname": "RemainingPaymentMadeForAssetAcquisitionMilestone", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_RemainingPaymentMadeForBusinessCombinationMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remaining Payment Made For Business Combination Milestone", "label": "Remaining Payment Made For Business Combination Milestone", "terseLabel": "Remaining payment made for business combination milestone" } } }, "localname": "RemainingPaymentMadeForBusinessCombinationMilestone", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Repayment of outstanding promissory notes and accrued interest received.", "label": "Repayment Of Outstanding Promissory Notes And Accrued Interest Received", "terseLabel": "Repayment of outstanding promissory notes and accrued interest received" } } }, "localname": "RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense under license agreement", "label": "Research and development expense under license agreement" } } }, "localname": "ResearchAndDevelopmentExpenseUnderLicenseAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_ResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.", "label": "Research And Development Expenses Current", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensesCurrent", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vir_RestrictedStockAwardsRSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock awards (RSA).", "label": "Restricted Stock Awards R S A [Member]", "terseLabel": "Restricted Stock Awards (RSAs)" } } }, "localname": "RestrictedStockAwardsRSAMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restricted stock liability recognized for portion of promissory note repayment.", "label": "Restricted Stock Liability Recognized For Portion Of Promissory Note Repayment", "terseLabel": "Restricted stock liability recognized for portion of promissory note repayment" } } }, "localname": "RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_RestrictedStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock purchase agreement.", "label": "Restricted Stock Purchase Agreement [Member]", "terseLabel": "Restricted Stock Purchase Agreement" } } }, "localname": "RestrictedStockPurchaseAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_RockefellerAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rockefeller agreement.", "label": "Rockefeller Agreement [Member]", "terseLabel": "Rockefeller Agreement" } } }, "localname": "RockefellerAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_RockefellerUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rockefeller University.", "label": "Rockefeller University [Member]", "terseLabel": "Rockefeller" } } }, "localname": "RockefellerUniversityMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_RoyaltiesBasedOnNetSalesOfLicensedProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties payment based on net sales of licensed products.", "label": "Royalties Based on Net Sales of Licensed Products", "verboseLabel": "Royalties based on net sales of licensed products" } } }, "localname": "RoyaltiesBasedOnNetSalesOfLicensedProducts", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_RoyaltiesPaymentExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of years that royalties payment expired.", "label": "Royalties Payment Expiration Period", "verboseLabel": "Royalties payment expiration period" } } }, "localname": "RoyaltiesPaymentExpirationPeriod", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties payment range on net sales of licensed product.", "label": "Royalties Payment Range on Net Sales of Licensed Product", "terseLabel": "Royalties payment range on net sales of licensed product" } } }, "localname": "RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty obligation period from date of first commercial sale.", "label": "Royalty Obligation Period From Date Of First Commercial Sale", "terseLabel": "Royalty obligation period from date of first commercial sale" } } }, "localname": "RoyaltyObligationPeriodFromDateOfFirstCommercialSale", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty payment obligation expiration period after first commercial sales.", "label": "Royalty Payment Obligation Expiration Period After First Commercial Sales", "terseLabel": "Royalty payment obligation expiration period after first commercial sales" } } }, "localname": "RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_SARSCoV2ProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SARS-CoV-2 product.", "label": "S A R S Co V2 Product [Member]", "terseLabel": "SARS-CoV-2 Product" } } }, "localname": "SARSCoV2ProductMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_SaleLeasebackTransactionProceedsFromFinancingObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "sale leaseback transaction proceeds from financing obligations.", "label": "Sale Leaseback Transaction Proceeds From Financing Obligations", "terseLabel": "Proceeds from sale leaseback of financing obligation" } } }, "localname": "SaleLeasebackTransactionProceedsFromFinancingObligations", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_SaleOfStockConsiderationAggregateOfferingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate offering price for which the entity may sell shares of its common stock under the sales agreement.", "label": "Sale Of Stock Consideration Aggregate Offering Price", "terseLabel": "Aggregate offering price" } } }, "localname": "SaleOfStockConsiderationAggregateOfferingPrice", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_SalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales agreement.", "label": "Sales Agreement [Member]", "terseLabel": "Sales Agreement" } } }, "localname": "SalesAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_SalesMilestonesAchieved": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales milestones achieved during the reporting period", "label": "Sales Milestones Achieved", "terseLabel": "Sales milestone achieved" } } }, "localname": "SalesMilestonesAchieved", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_SamsungBiologicsCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Samsung Biologics Co., Ltd.", "label": "Samsung Biologics Company Limited [Member]", "terseLabel": "Samsung Biologics Co., Ltd" } } }, "localname": "SamsungBiologicsCompanyLimitedMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of accrued liabilities and other liabilities.", "label": "Schedule Of Accrued Liabilities And Other Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued and Other Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and intangible assets.", "label": "Schedule Of Goodwill And Intangible Assets [Line Items]", "terseLabel": "Schedule of Goodwill and Intangible Assets [Line Items]" } } }, "localname": "ScheduleOfGoodwillAndIntangibleAssetsLineItems", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_ScheduleOfGoodwillAndIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and intangible assets.", "label": "Schedule Of Goodwill And Intangible Assets [Table]", "terseLabel": "Schedule Of Goodwill And Intangible Assets [Table]" } } }, "localname": "ScheduleOfGoodwillAndIntangibleAssetsTable", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of operating lease amounts recorded in condensed consolidated balance sheet.", "label": "Schedule Of Operating Lease Amounts Recorded In Condensed Consolidated Balance Sheet Table [Text Block]", "terseLabel": "Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet" } } }, "localname": "ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "vir_SecondPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second plan.", "label": "Second Plan [Member]", "terseLabel": "Second Plan" } } }, "localname": "SecondPlanMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_SeriesAOneConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A-1 convertible preferred stock.", "label": "Series A One Convertible Preferred Stock [Member]", "terseLabel": "Series A-1 Convertible Preferred Stock" } } }, "localname": "SeriesAOneConvertiblePreferredStockMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "vir_SeriesATwoConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A -2 convertible preferred stock member.", "label": "Series A Two Convertible Preferred Stock [Member]", "terseLabel": "Series A-2 Convertible Preferred Stock" } } }, "localname": "SeriesATwoConvertiblePreferredStockMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "vir_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B convertible preferred stock.", "label": "Series B Convertible Preferred Stock [Member]", "terseLabel": "Series B Convertible Preferred Stock" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "vir_SpecifiedClinicalDevelopmentMilestonesPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Specified clinical development milestones payment.", "label": "Specified Clinical Development Milestones Payment", "terseLabel": "Specified clinical development milestones payment" } } }, "localname": "SpecifiedClinicalDevelopmentMilestonesPayment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expenses related to certain development milestone payments", "label": "Specified Research And Development Expenses Milestone Payments", "terseLabel": "Specified research and development expenses milestone payments" } } }, "localname": "SpecifiedResearchAndDevelopmentExpensesMilestonePayments", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_SpecifiedSalesDevelopmentMilestonesPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Specified sales development milestones payment.", "label": "Specified Sales Development Milestones Payment", "terseLabel": "Specified sales development milestones payment" } } }, "localname": "SpecifiedSalesDevelopmentMilestonesPayment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vested shares related to repayment of promissory notes.", "label": "Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Shares", "terseLabel": "Repayment of promissory notes, net of unvested shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of promissory notes related to vested shares.", "label": "Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Value", "terseLabel": "Repayment of promissory notes, net of unvested shares" } } }, "localname": "StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "vir_StockIssuedDuringPeriodSharesAchievementOfMilestone": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares achievement of milestone.", "label": "Stock Issued During Period Shares Achievement Of Milestone", "terseLabel": "Issuance of common stock in connection with the achievement of a milestone (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAchievementOfMilestone", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares cashless exercise of warrant.", "label": "Stock Issued During Period Shares Cashless Exercise Of Warrant", "terseLabel": "Issuance of common stock for cashless exercise of warrant (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "vir_StockIssuedDuringPeriodSharesCollaborationAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in connection with a collaboration agreement.", "label": "Stock Issued During Period Shares Collaboration Agreement", "terseLabel": "Issuance of common stock in connection with a collaboration agreement (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCollaborationAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for settlement of contingent consideration.", "label": "Stock Issued During Period Shares Issued For Settlement Of Contingent Consideration", "terseLabel": "Issuance of common stock to settle a contingent consideration (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "vir_StockIssuedDuringPeriodSharesLicenseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock issued in connection with a license agreement.", "label": "Stock Issued During Period Shares License Agreement", "terseLabel": "Issuance of common stock in connection with a license agreement (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesLicenseAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "vir_StockIssuedDuringPeriodValueAchievementOfMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value achievement of milestone.", "label": "Stock Issued During Period Value Achievement Of Milestone", "terseLabel": "Issuance of common stock in connection with the achievement of a milestone" } } }, "localname": "StockIssuedDuringPeriodValueAchievementOfMilestone", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "vir_StockIssuedDuringPeriodValueCollaborationAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in connection with a collaboration agreement.", "label": "Stock Issued During Period Value Collaboration Agreement", "terseLabel": "Issuance of common stock in connection with a collaboration agreement" } } }, "localname": "StockIssuedDuringPeriodValueCollaborationAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued for settlement of contingent considerations.", "label": "Stock Issued During Period Value Issued For Settlement Of Contingent Consideration", "terseLabel": "Issuance of common stock to settle a contingent consideration" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "vir_StockIssuedDuringPeriodValueLicenseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of common stock issued in connection with a license agreement.", "label": "Stock Issued During Period Value License Agreement", "terseLabel": "Issuance of common stock in connection with a license agreement" } } }, "localname": "StockIssuedDuringPeriodValueLicenseAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "vir_StockIssuedDuringPeriodWarrantExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the exercise of warrant during the period.", "label": "Stock Issued During Period Warrant Exercised", "terseLabel": "Common stock shares issued for conversion of warrants" } } }, "localname": "StockIssuedDuringPeriodWarrantExercised", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vir_StockIssuedGrantAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total common stock issued in connection with the grant agreement.", "label": "Stock Issued Grant Agreement", "terseLabel": "Common stock issued in connection with the grant agreement" } } }, "localname": "StockIssuedGrantAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of lease cost and other information related to operating leases.", "label": "Summary Of Lease Cost And Other Information Related To Operating Leases Table [Text Block]", "terseLabel": "Summary of Lease Costs and Additional Information Related to Operating Leases" } } }, "localname": "SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "vir_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vir_TaxCreditCarryforwardsExpirationBeginningYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carryforwards expiration beginning year.", "label": "Tax Credit Carryforwards Expiration Beginning Year", "verboseLabel": "Tax credit carryforwards expiration beginning year" } } }, "localname": "TaxCreditCarryforwardsExpirationBeginningYear", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "vir_TemporaryEquityAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity additional shares authorized.", "label": "Temporary Equity Additional Shares Authorized", "terseLabel": "Convertible preferred stock, additional shares authorized" } } }, "localname": "TemporaryEquityAdditionalSharesAuthorized", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of convertible preferred stock into common stock shares.", "label": "Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock", "negatedLabel": "Conversion of convertible preferred stock into common stock" } } }, "localname": "TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "vir_TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of convertible preferred stock into common stock shares.", "label": "Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock Shares", "negatedLabel": "Conversion of convertible preferred stock into common (in shares)" } } }, "localname": "TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of convertible preferred stock, net of issuance cost (in Shares)", "verboseLabel": "Convertible preferred stock, shares sold" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "vir_TemporaryEquityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of key terms, rights and preferences of convertible preferred stock.", "label": "Temporary Equity [Text Block]", "terseLabel": "Convertible Preferred Stock" } } }, "localname": "TemporaryEquityTextBlock", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "vir_TenantImprovementAllowanceAggregate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount of tenant improvement allowance available.", "label": "Tenant Improvement Allowance Aggregate", "terseLabel": "Tenant improvement allowance" } } }, "localname": "TenantImprovementAllowanceAggregate", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_ThirdClosingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third closing.", "label": "Third Closing [Member]", "terseLabel": "Third Closing" } } }, "localname": "ThirdClosingMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TomegaVaxIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TomegaVax, Inc.", "label": "Tomega Vax Inc [Member]", "terseLabel": "TomegaVax" } } }, "localname": "TomegaVaxIncMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "vir_TuberculosisTBGrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tuberculosis (\u201cTB\u201d) grant.", "label": "Tuberculosis T B Grant [Member]", "terseLabel": "Tuberculosis (\"TB\") Grant" } } }, "localname": "TuberculosisTBGrantMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandAndTwentyGskAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Twenty GSK Agreement Member", "label": "Two Thousand And Twenty GSK Agreement Member", "terseLabel": "2020 GSK Agreement" } } }, "localname": "TwoThousandAndTwentyGskAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandAndTwentyOneGSKAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 GSK Agreement [Member]", "label": "Two Thousand And Twenty One G S K Agreement [Member]", "terseLabel": "2021 GSK Agreement" } } }, "localname": "TwoThousandAndTwentyOneGSKAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandAndTwentyOneGSKCollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 GSK Collaboration [Member]", "label": "Two Thousand And Twenty One G S K Collaboration [Member]", "terseLabel": "2021 GSK Collaboration" } } }, "localname": "TwoThousandAndTwentyOneGSKCollaborationMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty one preliminary collaboration agreement and stock purchase agreement.", "label": "Two Thousand And Twenty One Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]", "terseLabel": "2021 Preliminary Collaboration Agreement and Stock Purchase Agreement" } } }, "localname": "TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty preliminary collaboration agreement and stock purchase agreement.", "label": "Two Thousand And Twenty Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]", "terseLabel": "2020 Preliminary Collaboration Agreement and Stock Purchase Agreement" } } }, "localname": "TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]", "label": "Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]", "terseLabel": "2019 and 2020 Xencor Agreement member" } } }, "localname": "TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandNineteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen employee stock purchase plan.", "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]", "terseLabel": "2019 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandNineteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen equity incentive plan.", "label": "Two Thousand Nineteen Equity Incentive Plan [Member]", "terseLabel": "2019 Equity Incentive Plan" } } }, "localname": "TwoThousandNineteenEquityIncentivePlanMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandNineteenXencorAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen xencor agreement.", "label": "Two Thousand Nineteen Xencor Agreement [Member]", "terseLabel": "2019 Xencor Agreement" } } }, "localname": "TwoThousandNineteenXencorAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandSeventeenGrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand seventeen grant.", "label": "Two Thousand Seventeen Grant [Member]", "terseLabel": "2017 Grant" } } }, "localname": "TwoThousandSeventeenGrantMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandSixteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand sixteen equity incentive plan.", "label": "Two Thousand Sixteen Equity Incentive Plan [Member]", "terseLabel": "2016 Equity Incentive Plan" } } }, "localname": "TwoThousandSixteenEquityIncentivePlanMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand wenty Glaxo Wellcome UK Limited and Beecham S.A.", "label": "Two Thousand Twenty Glaxo Wellcome U K Limited And Beecham S A [Member]", "terseLabel": "2020 GSK" } } }, "localname": "TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one Glaxo Wellcome UK Limited and Beecham S.A.", "label": "Two Thousand Twenty One Glaxo Wellcome U K Limited And Beecham S A [Member]", "terseLabel": "2021 GSK" } } }, "localname": "TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandTwentyOneStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty one stock purchase agreement.", "label": "Two Thousand Twenty One Stock Purchase Agreement [Member]", "terseLabel": "2021 Stock Purchase Agreement" } } }, "localname": "TwoThousandTwentyOneStockPurchaseAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandTwentyStockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty stock purchase agreement.", "label": "Two Thousand Twenty Stock Purchase Agreement [Member]", "terseLabel": "2020 Stock Purchase Agreement" } } }, "localname": "TwoThousandTwentyStockPurchaseAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_TwoThousandTwentyXencorAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty xencor agreement.", "label": "Two Thousand Twenty Xencor Agreement [Member]", "terseLabel": "2020 Xencor Agreement" } } }, "localname": "TwoThousandTwentyXencorAgreementMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_UnusedFundsReceivedInAdvance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unused funds received in advance.", "label": "Unused Funds Received In Advance", "terseLabel": "Unused funds received in advance" } } }, "localname": "UnusedFundsReceivedInAdvance", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_UpfrontFeePaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront fee paid.", "label": "Upfront Fee Paid", "terseLabel": "Upfront fee paid" } } }, "localname": "UpfrontFeePaid", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_UpfrontPaymentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment receivable.", "label": "Upfront Payment Receivable", "terseLabel": "Upfront payment receivable" } } }, "localname": "UpfrontPaymentReceivable", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_VaccineProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vaccine Program.", "label": "Vaccine Program [Member]", "terseLabel": "Vaccine Program" } } }, "localname": "VaccineProgramMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_ValueOfCommonStockSharesIssuedForMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of common shares issued for milestone payment.", "label": "Value of common stock shares Issued for milestone payment", "terseLabel": "Value of common stock shares Issued for milestone payment" } } }, "localname": "ValueOfCommonStockSharesIssuedForMilestonePayment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_ValueOfSharesTransferredToCollaborator": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares transferred to collaborator under the terms of the collaboration agreement.", "label": "Value of shares transferred to collaborator" } } }, "localname": "ValueOfSharesTransferredToCollaborator", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_ValueStockIssuedGrantAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total value of common stock issued in connection with the grant agreement.", "label": "Value Stock Issued Grant Agreement", "terseLabel": "Value of common stock issued in connection with the grant agreement" } } }, "localname": "ValueStockIssuedGrantAgreement", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vir_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase common stock.", "label": "Warrants To Purchase Common Stock [Member]", "terseLabel": "Warrants to Purchase Common Stock" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" ], "xbrltype": "domainItemType" }, "vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice period for licensed program, uncured material breach.", "label": "Written Notice Period For Licensed Program Uncured Material Breach", "terseLabel": "Written notice period for uncured material breach" } } }, "localname": "WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WrittenNoticePeriodForTerminationOfLicensedProgram": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice period for termination of licensed program.", "label": "Written Notice Period For Termination Of Licensed Program", "terseLabel": "Written notice period for termination of licensed program" } } }, "localname": "WrittenNoticePeriodForTerminationOfLicensedProgram", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WrittenNoticePeriodToTerminateAgreementByCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice period to terminate agreement by company.", "label": "Written Notice Period to Terminate Agreement by Company", "terseLabel": "Written notice period to terminate agreement by company" } } }, "localname": "WrittenNoticePeriodToTerminateAgreementByCompany", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WrittenNoticePeriodToTerminateAgreementByCounterparty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice period to terminate agreement by counterparty.", "label": "Written Notice Period to Terminate Agreement by Counterparty", "terseLabel": "Written notice period to terminate agreement by counterparty" } } }, "localname": "WrittenNoticePeriodToTerminateAgreementByCounterparty", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice period to terminate licensed program for failure to make payment.", "label": "Written notice period to terminate licensed program for failure to make payment", "terseLabel": "Written notice period to terminate licensed program for failure to make payment" } } }, "localname": "WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice period to terminate licensed program for uncured material breach.", "label": "Written notice period to terminate licensed program for uncured material breach" } } }, "localname": "WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.", "label": "Written Notice period to terminate licensed program if under challenge" } } }, "localname": "WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.", "label": "Written Notice period to terminate licensed program if under challenges" } } }, "localname": "WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WrittenNoticeToTerminateLicensedProgramIfExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice to terminate licensed program following the exercise of an option for such program.", "label": "Written notice to terminate licensed program if exercise" } } }, "localname": "WrittenNoticeToTerminateLicensedProgramIfExercise", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Written notice to terminate licensed program if not exercise.", "label": "Written notice to terminate licensed program if not exercise", "terseLabel": "Written notice to terminate licensed program if not exercise" } } }, "localname": "WrittenNoticeToTerminateLicensedProgramIfNotExercise", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vir_WuXiBiologicsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WuXi Biologics Limited.", "label": "Wu Xi Biologics Limited [Member]", "terseLabel": "WuXi Biologics" } } }, "localname": "WuXiBiologicsLimitedMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails", "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WuXi biologics and Samsung letter agreement assignments and master services agreements.", "label": "Wuxi Biologics And Samsung Letter Agreement Assignments And Master Services Agreements [Member]", "terseLabel": "WuXi Biologics MSA and Samsung MSA" } } }, "localname": "WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_XencorAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xencor Agreements.", "label": "Xencor Agreements [Member]", "verboseLabel": "Xencor Agreements" } } }, "localname": "XencorAgreementsMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vir_XencorIncorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xencor, incorporation member.", "label": "Xencor Incorporation [Member]", "terseLabel": "Xencor" } } }, "localname": "XencorIncorporationMember", "nsuri": "http://www.vir.bio/20211231", "presentation": [ "http://www.vir.bio/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1828-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2062-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2538-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "48", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2538-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2574-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2597-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2600-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "54", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2603-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121329188&loc=SL108377954-173880" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121554622&loc=d3e15372-109273" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123573877&loc=SL118137113-114923" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r459": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r507": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r531": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420" }, "r537": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r551": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=107671284&loc=SL5844817-113951" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515679&loc=d3e40733-113955" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123589689&loc=d3e48542-113965" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=56949186&loc=d3e50579-113967" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117817908&loc=SL117819236-161440" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r601": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r630": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r636": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r746": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r747": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r748": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r749": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r750": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r751": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r752": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r753": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r754": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r755": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r756": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" } }, "version": "2.1" }